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ABSTRACT 
 
This thesis dissertation presents the collective research into the advancement of 
mesoporous silicate particles as biointerface devices, the development of new materials and 
the application of these particles as solid supports for heterogeneous catalysis. 
Mesoporous silica has been utilized in the aforementioned applications due to several 
reasons; the first being the ability to achieve high surface areas (500 – 1000 m2 g-1) with 
controlled pore sizes and particle morphology. Another reason for their popularity is their 
robustness in applications of heterogeneous catalysis and readily functionalizable surface 
with a wide variety of organic groups. In the field of biointerface devices, mesoporous silica 
nanoparticles represent a class of materials that exhibit high biocompatibility. In addition, the 
ability to functionalize the surfaces (outer surface and pore interiors) allows the particles to 
be targeted to specific cell types as well as optimized to release many different therapeutic 
molecules under specific stimuli. 
A unique particle coating consisting of a chemically cleavable lipid bilayer that 
allows for the encapsulation of a fluorescent molecule and increases the biocompatibility of 
the particle has been developed. The lipid bilayer coated mesoporous silica nanoparticle (LB-
MSN) was characterized using X-ray diffraction, transmission electron microscopy and 
nitrogen ‘sorption isotherms. The finished LB-MSN was then incubated with mammalian 
cells in order to demonstrate their biocompatibility. Confocal micrographs demonstrate the 
endocytosis of the particles into the cells. In addition the micrographs also show that the LB-
MSNs are separate from the endosomal compartments, however due to the lipophilic nature 
of the dye used to label the endosome there is some debate regarding this conclusion. The 
lipid bilayer coating was then applied to a large pore MSN (l-MSN) which had been 
previously shown to cause lysis of red blood cells (RBCs) at low concentrations of particles. 
The lipid bilayer allowed the LB-MSN to interface with RBCs without resulting in 
haemolysis. It was observed however, that spiculation (damage) of the RBCs still occurred 
despite the lack of cell lysis. During the course of the study, the composition of the outer 
x 
 
leaflet of the lipid bilayer was altered to more closely match that of the outer leaflet of RBCs. 
This alteration proved to make the LB-l-MSN particle extremely compatible with RBCs in 
that spiculation of the cells was reduced by more than 50 % according to observations by 
scanning electron microscopy.    
A new synthetic route to mesoporous silica nanoparticles (MSNs) was developed 
using water in oil (W/O) emulsions. This method relies on the presence of an amphiphilic 
stabilizer molecule to control the size and quality of the spherical morphology of the 
particles. Partitioning of the oil phase into cetyltrimethylammonium bromide surfactant 
molecules is implicated in expanding the size of the mesopores from the standard 3 nm pore 
to 7 nm. This material is extensively characterized using X-ray diffraction techniques and 
TEM microscopy. Chapter 3 also outlines the synthesis of a new periodic mesoporous 
organosilica (PMO) in which the bridging organic group is a benzobisoxazole molecule 
synthesized in the research group of Dr. Malika Jeffries-EL. While no immediate application 
of this new particle was proven, we propose this structure as the basis for a new class of light 
harvesting or light emitting diode material based on the performance of the polymers 
containing these benzobisoxazole moieties and functionalized dyes.                     
The final project was the initial development of an N-heterocyclic carbene ligand 
based on an imidazole framework. This project represents significant synthetic challenges in 
that the pattern of substitution on the imidazole framework has not been reported in the 
literature to the best of our knowledge. Despite the synthetic challenges, significant progress 
has been made towards the goal of generating an MSN with a functional group capable of 
coordinating a wide variety of metals for an extensive array of catalytic reactions. 
Additionally, N-heterocyclic carbenes have been shown to have anti-bacterial and anti-tumor 
capabilities. We propose that these new ligands may also represent a significant advancement 
in the field of biomedical applications of MSNs.         
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Chapter 1: Mesoporous Silica Particles in Biological 
Applications 
I. Introduction 
Mesoporous silica particles (MSPs) have been used for over a decade to affect changes 
and analyze biological systems. These particles exhibit characteristics such as high surface 
area capable of accepting diverse functionalization, relatively large internal volumes for 
storage of different molecules and the ability to selectively functionalize either the inner or 
outer surface areas of the particle. In addition, particle size and morphology can also be 
successfully tuned to match specifics needs of the application.  
 
Figure 1. Timeline of different studies using MSP systems. Reprinted with permission from Lin, Y.-S.; et al. 
Phys. Chem. Lett. 2012, 3, 364 – 274. Copyright 2012 American Chemical Society. 
The combinations of these attributes can lead to a dizzying array of parameters that 
should be known if the MSP system is to be properly evaluated for effectiveness. One recent 
review focused exclusively on the synthetic aspect of MSPs and concluded that the majority 
of systems developed for use in biological applications do not meet many of the physical 
criteria required to go from bench top to bedside.[1] These criteria include particle size, pore 
structure, aggregation of particles and biodegradability. While controlling synthetic 
conditions to provide the optimal particle for the application is one necessity of bio-destined 
MSPs, another is adopting the correct particle characterization techniques and assays for 
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evaluating the performance and toxicity of the MSP in the biological system being studied. 
Bio-destined MSPs have been under development for over 10 years and are showing 
potential as possible therapeutic devices and delivery agents. With this in mind, it is 
important that researchers studying the biological applications of MSPs (and indeed 
nanoparticles in general) adopt a set of criteria which will enable the fair evaluation for all 
future work done in this field. This will be the focus of section III of the review, wherein the 
strictly toxicological studies of MSPs will be evaluated. Further sections of this review will 
attempt to provide some perspective on the diversity of MSP systems that are available to 
study.       
II. Toxicity Studies and Mesoporous Silicates 
One of the greatest challenges facing researchers designing MSPs for drug delivery lies 
in understanding the toxicology and development of a uniform set of standards for 
determining the safety and effectiveness of MSPs. Recently the journal Nature published a 
short editorial on the inadequacies of several in vivo and in vitro methods claiming that 15 of 
21 animal studies failed to meet the highest criteria of the Klimisch test.[2, 3] The article goes 
on to state “Of 10 parameters that… should be in a nanotoxicity study, such as particle size, 
shape and surface chemistry, more than half were missing from the 14 animal studies.” This 
study was brought about in part by a paper in the European Respiratory Journal in which 
Song et al. report that seven Chinese factory workers developed pleural granulomas 
(aggregations of immune cells in the lung lining) and excessive discolored fluid in the lung 
lining.[4] All cases examined were found to have high concentrations of ≈30 nm polyacrylate 
ester particles in the lung fluid and tissue. A second editorial in Nature points out that several 
experts regard the study as being inconclusive regarding nanoparticles being the cause of 
respiratory distress in the workers; however it was stated that the evidence “raises the bar for 
doing appropriate research… when working with nanomaterials”.[5] A reply made by an 
author of one of the evaluated studies points out that much of the data that is missing in the 
study is actually available in previous papers published by their research group, however this 
is akin to a pharmaceutical company claiming that two batches of drug have identical 
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properties without doing any physical analyses, which would not be allowed under FDA 
guidelines.  
This section is devoted to a serious review of toxicological studies of MSPs for use in 
biological systems and an attempt to quantify the quality of data coming from several 
toxicological studies, the Klimisch criteria will be applied and a ranking of reports will be 
provided (Klimisch criteria are available in appendix A). While it is true that all Klimisch 
score criteria are not precisely defined, this approach presents the most uniform method for 
evaluating a large number of studies.  In addition, inconsistencies regarding in vitro toxicity 
evaluation methods have already been observed by several groups and these will be 
discussed in an attempt to determine the best method(s) for assessing toxicity.  
Over the last five years, several groups have attempted to quantify the toxicity and 
bioaccumulation of MSPs and nanoparticles in general. The majority of work describing the 
cytoxicity of MSPs involves unfunctionalized nanoparticles and attempts to correlate the 
toxicity with physical parameters such as particle size, pore size and particle morphology. 
Silica particles bearing absorbed or grafted polyethylene glycol (PEG) groups are also 
evaluated for their toxicity, owing to the relatively recent findings that many materials, when 
coated with PEG do not actively interact with cells and do not participate in non-specific 
protein binding. One broad review on nanoparticles suggests that reproducibility in data may 
be affected by interference of nanoparticles with read-out systems commonly used to 
determine cytotoxicity.[6, 7] Indeed, false data have been observed in a number of studies in 
which methotrexate (MTT) was employed, including one report where it was discovered that 
a standard MTT assay gave falsely high compatibility results due to  reduction of MTT at the 
surface of an MSP instead of through normal cellular metabolism.[8] A further study reported 
that MTT data was unreliable due to the ability of MSPs to increase the rate of formazan 
(MTT metabolite) exocytosis, falsely increasing the biocompatibility of MSPs.[9] Despite this 
finding, MTT is still widely applied to determine toxicity of nanomaterials, perhaps due to 
the availability and cost of kits and the fact that only a fluorometer is necessary for data 
collection. 
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Figure 2. Graph representing the percentage of formazan detected from the reduction of (3-[4,5-
dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide) (MTT) in the presence of MSPs. Anodized = Si-C 
surface, TOPSi = thermally oxidized (calcined), TCPSi = thermally carbonized. The sample TOPSi represents 
the surface most similar to the MSPs reviewed in this chapter. Reprinted with permission from Laaksonen, T.; 
et al., Chemical Research in Toxicology 2007, 20 (12), 1913-1918. Copyright 2007 American Chemical Society 
Unfortunately, due to the number of earlier studies that rely on MTT assays for toxicity 
measurements, much of our knowledge regarding the toxicity of MSPs must be carefully 
examined and studies using MTT must include a clear negative control group in which MTT 
and MSPs are co-incubated in growth media to ensure validity of observations. 
Toxicity of MSPs in vitro 
  In order to bypass some of the problems found in their earlier studies, Heikkila et al. 
have chosen several assays that rely on different metabolic indicators to determine overall 
toxicity of sieved particle aggregates.[10] Different kits for measuring cell viability were used, 
including protease activity, ATP luminescence, and caspase 3/7 activity in addition to flow 
cytometry and ROS detection in order to ensure accurate results of individual methods. 
Protease and ATP-luminescence (Fig. 3) assays gave remarkably similar results for percent 
cell viability and the caspase 3/7 assay for apoptosis activity results showed that in 
experiments with less cell viability, the caspase 3/7 activity was increased. The peroxide 
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Figure 3. Results of the ATP luminescence assay in Caco-2 cells. Deemed the most accurate and sensitive 
indicator of cell viability. Reprinted with permission from Heikkilae, T.; et al., Euro. J. Pharma Biopharma 
2010, 74 (3), 483-494. Copyright 2010 Elsevier Publishing. 
A study by Al Shamsi et al. uses a novel method of examining the oxygen 
consumption of excised mouse organ tissue; this is believed to be the only example utililizing 
this oxygen consumption n technique with MSPs.[11] In this work the authors determined that 
MCM-41 and SBA-15 type MSPs are biocompatible under specific conditions in vitro. One 
thing to note in this study is the large diameter and broad size distribution (600 to 1000 nm) 
of MCM-41 particles examined. In most systems describing MCM-41 type MSPs the average 
particle size is approximately 200 nm ± 50 nm. As the size of a particle is widely accepted as 
one of the main determining factors of toxicity, care must be exercised when attempting to 
correlate the findings of this study with other toxicological studies of MCM-41 type particles. 
Huang and coworkers examined the toxicity of MSPs with different morphologies but similar 
diameters using such diverse assays as cytoskeleton formation, cell adhesion, Western blot, 
cell migration, PCR-assisted protein quantification, annexin V apoptosis assay and MTT 
assay.[12]  The majority of findings in this study indicate that particles with higher aspect 
ratios (i.e. rod-shaped particles) interfere more with cellular processes such as adhesion, 
cytoskeletal organization and protein synthesis than spherical particles resulting in an 
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approximately 10 -20% increase of cells undergoing apoptosis over the control group. In 
contrast to the latter findings, the MTT assay for viability showed that almost all particle 
types and exposure concentrations resulted in cells that were at or above 100% viability and 
the particles were judged non-toxic based on this evidence.  
Another study on the effects of particle size on cell viability by He an coworkers 
shows similar results for the MTT assay as the previous study.[13]Additionally, this study 
showed that the toxicity of particles where the templating surfactant has been removed 
 
Figure 4.  Results of the viability assays for MAD-MB-468 cells (A) and COS-7 cells (B). E-MS and C-MS 
refer to solvent extracted (soxhlet) and calcined MSPs respectively.    
through solvent extraction is markedly increased compared to particles that have been 
calcined (Fig. 4). However, upon examination of the experimental evidence, the solvent 
extracted particles have an unusually high mass percentage of surfactant remaining compared 
with the majority of MSP publications. Control experiments with free surfactant were carried 
out; however a questionable correlation is drawn between the ζ-potential of the particles and 
the effect that surfactant within the pores of the particle plays on this measurement.[14]  Zeta-
potential measurements examine the charge at a defined distance from the surface of a solid. 
This distance is defined by the thickness of the inner and outer Helmholtz layers and the 
thickness of the slip plane (Figure X) which are all affected, in part, by the surface charge of 
the solid, pH, ionic strength and type of counter-ion as well as small amounts of impurity in 
solution. The distance of the MSP surface hypothetically altered by the presence of surfactant 
is too far from the slip plane to reasonable affect the measurement of ζ-potential if it is 
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assumed that diffusion of surfactant during extraction leads to the absence of surfactant at the 
pore openings.  
An important concern about the validity of toxicological studies is raised in a study 
by Zhang et al.[15] They point to the fact that most cell lines used for in vitro toxicity assays 
are genetically transformed and that there are numerous problems including cells without 
natural phenotype, different numbers of chromosomes, and differences in signaling and 
viability pathways between transformed and non-transformed cells. These differences, the 
authors state, result in large differences between in vivo and in vitro studies. To test an 
example of this hypothesis the authors use differentiated versus undifferentiated (primary) 
bronchial epithelial cells and compare cell viability after exposure to MSPs. Zhang et al. 
shows that there are measurable differences in toxicity for polyethyleneimine functionalized 
MSPs for differentiated and undifferentiated normal human bronchial epithelial (NHBE) 
cells. The increase in toxicity of MSPs toward differentiated NHBE cells result from 
increased binding of positively charged MSPs to negatively charged syndecan-1 proteins 
present on the surface of the differentiated cells. This finding was confirmed by treating 
NHBE cell lines with heparinase to cleave syndecan-1 from the surface of the cells, resulting 
in reduced MSP uptake and binding similar to that of undifferentiated NHBEs.  The results of 
these assays suggest that MSPs may become increasingly toxic after cells have differentiated 
in vivo.  
 
Figure 5. Assay of the mean fluorescence intensity (A) of fluorescein labeled MSPs. Differentiated cells show 
greater than 2 fold increase in intensity when larger PEI chains are used to coat the MSP. (B) Multiparametric 
heat map consisting of assays of calcium flux (Fluoro-4), superoxide generation (Mitosox), H2O2 generation 
(DCF) and mitochondrial membrane depolarization (JC-1). Reprinted with permission from Zhang, H.; et al. 
ACS Nano 2011, 5 (4), 2756-2769. Copyright 2011 American Chemical Society 
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Toxicity of MSPs in vivo 
Findings by Kohane and coworkers shows that various MSPs have highly variable in 
vivo toxicity depending on particle type and administration route.[16] Intraperitoneal 
administration resulted in the death of all test subjects for all particle types within 24 hours, 
while intravenous administration resulted in the death of all subjects within 15 minutes. 
Examination of lung tissue from deceased subjects indicated severe pulmonary thrombi and 
emboli. Subcutaneous delivery resulted in no death of subjects; this was hypothesized to be 
due to slow distribution of particles from the administration site.  Histology revealed that 
materials administered subcutaneously remained in the region of administration for a period 
of up to 3 months and that splenic deformation could be observed for 2 -3 months after 
exposure to MSPs.  
Similar findings were reported by Liu et al. with regards to 110 nm hollow MSPs in 
ICR mice at similar concentrations of particles (≈1200 mg/kg).[17] Liver enzymes alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST), both important indicators of 
liver health were found to be elevated in mice receiving over 80 mg/kg continuous 
intravenous dosages and liver necrosis, microgranulation and lymphocytic infiltration were 
observed for mice receiving a 1280 mg/kg bolus. Additionally, white blood cell count 
increased in mice receiving over 500 mg/kg doses of MSPs and in those receiving continuous 
intravenous doses  
Table 1. Details of a 90 day study on mortality rates of rats exposed to MSPs  
Materiala Mortalityb Time to deathc Numbers of animals euthanized for necropsy, by time point 
   
4 days 2 weeks 1 month 2 months 3 months 
 MCM-41cal 1 of 8 2 days 2 2 - 2 2 
 MCM-41ref 1 of 6 3 days 2 2 1 1 - 
 SBA-15 0 of 14 - 4 4 1 3 2 
 MCF 0 of 14 - 4 4 1 3 2 
 a 60 mg of MSP injected subcutaneously and at the sciatic nerve in the same animal 
b From presumed MSP toxicity 
c In animals that died from MSP toxicity 
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Figure 6. (a) Exposed peritoneum in mouse 24 hr post-injection of MSPs. Arrows indicate pockets of MSP 
residue. (b) Light microscopy image of mouse peritoneum, despite the presence of pockets of MSPs, 
mesothelial cells (arrows) do not appear to be damaged. Both table and figure are reprinted with permission 
from Hudson, S. P.; Padera, R. F.; Langer, R.; Kohane, D. S., Biomaterials 2008, 29 (30), 4045-4055. Copright 
2008 Elsevier Publishing. 
above 20 mg/kg, though not at levels outside of normal range until doses of 80 mg/kg were 
administered. The bioaccumulation of MSPs were also studied and found that MSPs are 
present for up to 4 weeks in the spleen and liver post administration. 
 In contrast to the unfunctionalized MSPs examined in the precious studys; MSPs 
functionalized with the tumor targeting ligand, folic acid were evaluated for in vivo toxicity 
by Lu et al.[18] Results of histology and silicon ICP-MS showed that folate-functionalized 
MSPs preferentially accumulate in tumor cells during the first 24 hours of the experiment. 
During the following 24 hours, folate functionalized MSPs migrate from the tumor sites (2-
fold decrease in MSP concentration in tumors) to the lung, spleen and intestine. After this 
time period MSPs are excreted (≈94.4% of the initial bolus) in the urine and feces of mice 
tested. A control study of untargeted MSPs showed an approximately 50% decrease in the 
amount of particles observed in tumors. During the course of this study several lever enzyme  
were also examined demonstrating elevated liver enzyme activity of alanine aminotransferase 
(ALT) and aspartate aminotransferase in mice receiving 0.5 mg bolus of MSPs though not in 
mice receiving 1.0 mg bolus, despite earlier findings that toxicity generally increases with 
particle concentration. Since exact times of subject analysis were included in this report, one 
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explanation of this result could be that ALT has a normal diurnal variation in concentration. 
Both ALT and AST are indicators of normal liver health. Liver enzymes were elevated again 
in mice receiving 2.0 mg bolus; however this concentration of MSPs was not used during the 
regular experiments. The number of eosinophils and neutrophils (types of white blood cells) 
were also observed to be elevated in the mice receiving 0.5 mg bolus and not in mice 
receiving 1.0 mg bolus. To determine long-term toxicity mice were administered two doses 
of MSPs per week for 8 weeks (18 injections total), body weight and observations for ascites 
were carried out every day and final histology results showed no systematic toxicity despite 
previous reports.  
Huang and coworkers recently expanded their previous in vitro work with an in vivo 
toxicology study detailing the biodistribution, clearance and toxicity of unfunctionalized and 
PEGylated rod shaped MSPs.[19] Silicon concentrations in the organs of test subjects were 
determined 2 hours, 24 hours and 7 days after receiving intravenous injections of MSPs (20 
mg/kg) either coated with PEG groups or unfunctionalized and possessing aspect rations of 
1.5 or 5 (AR1.5 and AR 5 respectively). Results of this assay indicate that the short term 
kinetics of biodistribution are more dependent upon the aspect ratios of the particles than the 
presence or absence of surface PEG groups. Particles with AR 1.5 were found more often in 
the liver, kidney and blood 2 hours after injection. Two surprising pieces of data were that 
PEGylated particles with AR5 were found in the lungs at levels twice that of all other particle 
types and that uncoated particles with AR5 were found in the spleen at levels four times that 
of the other particle  
 
Figure 7. Quantitative analysis of silicon concentration in tissue type by ICP-OES of near spherical (NSR) and 
long rod mesoporous silicates (NLR) and the PEGylated analogues, NSR-PEG and NLR-PEG. Reprinted with 
permission from Huang, X.; et al., ACS Nano 2011, 5 (7), 5390-5399. Copyright 2011 American Chemical 
Society 
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types. Within 24 hours, MSP levels in all organs and blood had essentially become equal 
except for the disproportionately high level of uncoated AR1.5 MSPs in the kidney. Lung 
tissue showed almost complete clearance of uncoated AR5 particles though PEGylated AR5 
particles were found at similar concentrations to other MSP types. After 7 days appreciable 
concentrations of all MSP types were found in the liver and concentrations of PEGylated 
AR1.5 MSPs were elevated in spleen and lung tissue. Total excretion percentage was not 
able to be determined due to fluctuating silicon levels in feces and urine of test subjects 
however, the majority of renal clearance occurs within 2 hrs post-injection followed by low 
levels in both urine and feces at 24 hours post-injection. After 7 days the majority of particles 
are found in test subject feces however the exact mechanisms under which excretion occurs 
remains unknown. All hematological test results came back within accepted normal ranges of 
controls for both 24 hour and 18 day test groups. Liver enzymes were found to be altered 
slightly, total bilirubin was lower than the control subjects after 24 hour but elevated in the 
18 day test group. The 18 day test group also showed decreased creatine concentrations and 
blood urea nitrogen was elevated for all particle types but more so for AR1.5 MSPs. The 
results of these studies indicate that at least at the lower concentrations examined, MSPs do 
not result in any short term or systematic toxicity in test subjects. 
He and coworkers have also recently examined the biodistribution and toxicity of both 
PEGylated and unPEGylated spherical MSPs with different diameters (80, 120, 200, and 360 
nm).[20]  Biodistribution results for mice intravenously injected with 20 mg/kg dosages of 
MSPs are uniform across all time points and particle sizes. The general trend is as follows; 
after 30 minutes a spike in silicon concentration is observed in the spleen and liver followed 
by a gradual decline over the course of the study. Unfortunately, information on 
concentrations of silica in control populations is unavailable for this study though it can be 
observed that both the liver and spleen retain a significant percentage of both PEGylated and 
unPEGylated MSPs with diameters of 80 nm and 120 nm after 30 days. In contrast to the 
MSP rods studied in the previous report, all MSPs were rapidly, though not completely, 
cleared from the lungs within 24 hours. Blood silicon concentrations were examined in order 
to determine the mean retention times (MRT) of MSPs. PEGylated particles showed a 
general increase of approximately 15 minutes over unPEGylated MSPs. Histopathology of all 
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subjects after 30 days post-injection showed no edema or erythema at the injection sight and 
fluorescence microscopy of organ tissue was deemed to show no acute pathological damage.     
Much research has been accomplished in proving at least a limited biocompatibility of 
MSPs in cells and in vivo. However, through evaluation of reports utilizing standardized 
criteria for toxicity evaluation (i.e. the Klimisch test) and careful examination of the reports 
summarized, only the most general conclusion can be reached about the toxicity of MSPs; 
that MSPs are biocompatible at low dosages and can be effectively cleared from tissue with 
limited exposures. The lack of a more specific conclusion is due to several factors including 
differing particle synthesis, in vitro studies in a variety of cell types, and in vivo studies. 
Examining the data in Table 1 shows that out of the 9 studies evaluated, there were 7 
different particle types and no two studies have used the same cell lines. While this differing 
information may make it difficult to see what MSPs are capable of or which one is the “best” 
or most biocompatible, the positive message is that all of the MSPs evaluated have at least a 
modicum of biocompatibility and that the framework SiO2 of MSPs is not overtly toxic. The 
future of MSPs in biological applications remains strong, in further sections of this chapter 
we will see specific examples of why MSPs are few systems available with the ability to be 
chemically tuned to provide to provide different types of drug release, cellular targeting, and 
diagnostic information all from the same framework.   
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III. Strategies for Controlled Release 
 
The ability to release cargo molecules in a controlled fashion upon the action of some 
stimulus has been a driving force behind mesoporous silicates (MSs) research as drug 
delivery devices. Ideally, a drug delivery system is designed to carry a pharmaceutical 
compound to a specific location in the body and release the pharmaceutical molecule in 
response to a unique set of stimulus found only at the target site. In this way many of the 
problems with current pharmaceutical technology can be remediated including drug toxicity 
and environmental contamination due to clearance of unmetabolized drug molecules.[21, 22] 
The types of stimuli that have been shown to cause the release of a cargo molecule can 
include chemical stimuli in the form of molecules and enzymes and physical stimuli such as 
light, heat pH, and magnetic fields. Reliable controlled release at physiological conditions is 
a challenging endeavor and the stimulus must be chosen carefully for a particular 
application.[23, 24]  Many of the stimuli studied are present in cells and tissue at concentrations 
adequate to cause release of the cargo. Systems utilizing cellular stimuli will be reviewed 
first. External release stimuli are usually dual purpose for example, in cancer cells, heating 
above 42oC causes cell death which can be combined with chemotherapy drug release. 
Similarly, magnetic fields may also be applied to cause local heating of “frustrated” magnetic 
particles resulting in both heating of the cell and sustained release of a therapeutic 
compound. In this section we will review the methods by which controlled release is affected 
in MSP systems. MSP systems whose controlled release is dependent on external stimuli are 
summarized in the last part of this section.   
Controlled Release with Cellular Stimuli 
Disulfide cleavage represents one of the largest areas of study with regards to MS-
based drug delivery devices; this may be due to its place as one of the first such systems 
discovered in 2003.[25-27]  In regards to biological stimuli, disulfide reducing agents such as 
glutathione, are nearly ubiquitous in all animal cell types and exist at concentrations of up to 
2 mM, making them ideal candidates as guest-release triggering molecules.[28] Methods for 
synthesis of disulfide-linked compounds and macromolecules also proceeds orthogonally 
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with other types of synthesis, making them reliable functional groups that are compatible and 
will not interfere with other functional groups found on capping molecules.  Tolerance of 
other functional groups allows disulfide bonds to be used in multi-functional systems, such as 
systems that are capable of targeting specific cell types or systems that can  
 
Figure 8. Examples of disulfide reducing agents used in the literature to affect controlled release.  
A second strategy for achieving controlled release under biological conditions is to use pH-
sensitive moieties as linkers between the caps and particles. Sensitivity towards pH allows 
scientists to use a variety of biological systems for affecting the release of a cargo molecule 
such as the pH change between stomach and small intestine, the pH of the 
endosome/lysosome and the increased pH of cancer cells.[38-42] Most of the controlled release 
activity in these systems is a result of the generation or elimination of ionic charges. The 
charges either attract or repel caps and pharmaceutical molecules which cause encapsulation 
or release of the pharmaceutical respectively. Several examples of this type of control can be 
seen when the drug doxorubicin (dox) is used as the entrapped pharmaceutical molecule. The 
amine group of doxorubicin can be associated with negatively charged groups like carboxylic 
acids and thus retained at pH below ≈ 8.0 and released upon deprotonation of dox and/or 
protonation of the carboxylic acid.[43] Alternatively, molecules such as polyethyleneimine can 
be utilized for their ability to conjugate dox at pH ≈ 8.0, when placed into media of lower 
pH, both dox and the polyethyleneimine can be protonated resulting in Coulombic release 
cargo under several different stimuli.[33, 37] Table 2 summarizes some of the MS systems that 
more prominently feature disulfide cleavage as their preferred method of affecting controlled 
release. repulsion and subsequent release of dox from the particle system.[44]   
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Table 3. Examples of MSPs utilizing disulfide-linked capping agents capable of controlled release of a guest 
molecule 
MS Particle Cap Stimulus Conc. [Stimulus] Reference 
Wormhole β-Cyclodextrin GSH/DTT 1 mM/1 mM Kim, C.[29] 
MCM-41 α-cyclodextrin/ cucurbit[6]uril EtSH/DTT Excess Ambrogio M.W.
[30] 
MCM-41 collagen DTT Unreported Luo, Z.[31] 
MCM-41 none NADH/DTT/DHLA/ GSH 1 mM Mortera, R
[32] 
MCM-41 Cadmium Sulfide EtSH/DTT 50 mM Lai, C.-Y
[25] 
MCM-41 β-Cyclodextrin DTT 35 mM Liu, R.[33] 
Core/Shell Dye Molecules GSH 10 mM Sauer, A[34] 
MCM-41 RAFT polymer DTT 20 mM Wan, X.[35] 
MCM-41 
PAMAM / 
Cadmium 
Sulfide 
EtSH/DTT/ 
TCEP 5 mM GruenHagen, J.
[36] 
MCM-41 Fe3O4 particle DTT 315 μM Giri, S.[27] 
 
 
Figure 9. Doxorubicin release from the pore of MSPs with varying pH. Around physiological pH doxorubicin 
is bound via static charge to the surface of the MSN. 
A review of some of pH active controlled release MS systems is summarized in table Y. 
Controlled release systems that depend on pH are usually responsive to other stimuli such as 
ionic strength. Casasús et al. has developed a system that in which a protonated polyamine 
cap counters the release of a squaraine dye by using Coulombic repulsion to prevent the dye 
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from passing the cap. The cap can then be removed either by raising the pH to ≥ 5.0 or by 
adding anions such as chloride, sulfate, or ATP to neutralize the charged caps, allowing 
squaraine to be released.[45] A second dual response system relies on a poly(N-
isopropylacrylamide) polymer (PNIPAM) to cap the pores of the MS particles.[46] 
Observation by dynamic light scattering techniques at physiological temperatures shows that 
the polymer coating contracts around the surface of the particle, forming a tightly capped 
network. When the pH is lowered to 6 and then to 5, the amount of carboxylate groups in the 
polymer decreases and electrostatic repulsions swell the polymer network, allowing or the 
release of dox in vivo .  
Boronic acids have also been utilized for pH dependant controlled release by Gan et 
al.[48] In this system Fe3O4 is linked to an 4-aminophenylboronic  acid (pKa ≈8.3), and the 
boronic acid is used to form a well known diol complex with a poly-ol functionally grafted to 
the MS particle.[56] One of the surprising attributes of this system is the persistence of the 
diol-boronic acid complex at pH below the pKa of the boronic acid, though this 
complexation behavior has been observed previously. The strength of the boronic acid/diol 
bond s such that release of cargo molecules is not observed until the pH of the solution is 
below 4. Another interesting attribute of this system is the reversible nature of the capping 
and uncapping reaction. In release experiments, the pH is adjusted to 3 and then to 7, at 
which time release of cargo molecules ceases until the pH is lowered to 3 again. A similar 
system was developed by Zhao et al in which insulin is functionalized with boronic acids and 
linked to the surface of MCM-41 particles using a similar strategy as the last report. Boronic 
acids also show specific binding affinity for different monosaccharides which has been 
utilized to release insulin in response to elevated glucose concentrations in this study.[57] 
Glucose responsive release occurs at biologically relevant concentrations for those suffering 
from diabetes. The pores of the MSP was also utilized to carry cyclic AMP (cAMP), which 
was released after the insulin caps dissociated from the particle.   
Table 4. Summary of MSP systems capable of controlled release of a guest molecule from the pore in response 
to a change in pH 
MS Particle Cap pH-Active Functionality 
Release 
Location 
Release 
pH Reference 
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MCM-41 None Ammonium Colon ≥ 7.4 Lee, C.-H.[47] 
MCM-41 Fe3O4 
4-aminophenyl-
boronic  acid 
MC3T3 - Bone 
Osteoblast 2 - 4 Gan, Q.
[48]  
MCM-41 None Carboxylic Acid MCF-7 - Breast Cancer 5.5 - 7.4 Gu, J.
[49] 
SBA-15 PMMA Carboxylic Acid HeLa - Cancer 7.0 Kim, T.-W.[50] 
MCM-41 triamine Ammonium Buffer only 5 - 6 Casasu, R.[45] 
Silica 
Nanotubes 
poly-
electrolyte 
Amine 
(doxirubicin) 
MCF-7 - Breast 
Cancer 1 - 4 Yang, Y.-J.
[43] 
MCM-41 none Amine Cancer Cells ≥ 8.0 Sun, G.[51] 
MCM-41 none Carboxylic Acid HeLa - Cancer 5.0 Park, H.-S.[52] 
MCM-41 polyethylene-imine 
Amine 
(doxirubicin) 
KB-V1 (mdr 
HeLa line) 5.0 Meng, H.
[53] 
MCM-41 β-cyclodextrin Imine Buffer only ≤ 6.0 Zhao, Y.-L.[54] 
MCM-41 β-cyclodextrin Benzimidazole THP-1 (leukemia) ≤ 6.0 Meng, H.
[44] 
MCM-41 None Hydrazone Hep-G2 (liver cancer) ≤ 4.5 Lee, C.
[55]-H. 
MCM-41 PNIPAM Carboxylic Acid HeLa - Cancer 6.0 - 5.0 Chang, B.[46] 
 
The last class of MSPs to rely on available cellular stimuli are systems that utilize 
enzymes to cleave the capping molecule from the particle to generate release. Very few 
reports of enzyme mediated controlled release are available, probably owing to the expense 
of many of the enzymes and the difficulty inherent in designing a molecule which can 
interact with the enzyme while still associated with the cap and particle. In one of the earliest 
examples, Patel et al. highlights the use of a previously reported α-cyclodextrin cap held in 
place with an ester-linked adamantly group.[58] The study shows that porcine liver esterase 
can effectively cleave the adamantly-ester bond causing α-cyclodextrin to diffuse away from 
the particle and affecting the release of the molecular cargo.  
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Carbohydrate polymers are also targets for enzymatic cleavage, Bernardos et al. have 
designed a system that relies on the disaccharide lactose as a cap. This system was designed 
with oral drug delivery in mind and initial reports show that there is no release of cargo under 
simulated gastric pH, however upon exposure to β-D-galactosidase, lactose is cleaved into 
glucose and galactose resulting in the release of encapsulated rhodamine B.[59] This work was 
expanded upon, where it was found that MS particles functionalized with a lactose 4-mer had 
the one of the highest loadings of dye molecules while maintaining the ability to release its 
cargo upon addition of β-D-galactosidase. Systems with shorter lactose chains had much 
smaller dye uptake values and systems with longer lactose chains were unable to effectively 
cap the mesopores resulting in cargo leaching.[60] The last system reviewed does not use an 
enzyme to directly cleave the cap from the particle, instead, Liu and coworkers have shown 
that cadaverine, generated from lysine and lysine decarboxylase can be used to competitively 
bind the cap, cucurbit[7]uril (C7U), and cause the release of encapsulated calcein.[61] 
Essentially, the authors show that cadaverine is a competitor for the pore of C7U and that 
cadaverine concentrations can be increased using enzymatic degradation of lysine to the 
point where the caps are released from the MSPs. 
 
Figure 10. Schematic representation of the synthesis of trehalose groups on the surface of the MSP followed by 
cleavage by an enzyme. Reprinted with permission from Bernardos, A.; et al., ACS Nano 2010, 4 (11), 6353-
6368. Copyright 2010 American Chemical Society 
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Controlled Release with External Stimuli     
In many cases, a viable internal stimulus cannot be found to affect controlled release 
in MS systems, leading to the use of a stimulus delivered from outside of the cell or body. 
One such stimulus that is currently under investigation is photo-assisted release. The most 
common method for photon-mediated release is to use a cap-particle linking molecule that is 
labile at a specific wavelength or sensitive to photo-generated electrons to cause the 
dissociation of a capping molecule. One of the first examples of photon-mediated release 
comes for the Zink and coworkers.[62]During the course of this study it was discovered that 
the 1:1 capping complex of [BHEEEN+CBPQT]4+ (BHEEEN = 1,5-bis[2-(2-(2-
hydroxyethoxy)ethoxy)ethoxy)naphthalene and CBPQT = cyclobis(paraquat-p-phenylene) 
could be sensitized to light by incorporating the photoresponsive molecule 9-anthracene 
carbocylic acid (ACA) and Ru(bpy)2(bpy(-CH2OH)2). When irradiated with the appropriate 
wavelength (364 nm and 457 nm, respectively) both ACA and Ru(bpy)2(bpy(-CH2OH)2) are 
able to transfer an electron to CBPQT4+, reducing its formal charge to 3+ and causing the 
rotaxane to diffuse away from the pores allowing the release of the guest molecules. Lin and 
coworkers designed a photo-labile system using a previously reported gold-MSN cap-particle 
system with a gold-linker molecule from the Rotello group.[63, 64] Irradiation at 365 nm for 10 
minutes was sufficient to release the drug paclitaxel from the MSN pore and cause a decrease 
greater than 50% in the viability of human liver cells. No significant cell death was reported 
for controls in which paclitaxel was not loaded into the pore. A third type of MS particle 
explored here does not feature a photo-labile cap, instead the drug molecule, chlorambucil, is 
linked to a surface-grafted coumarin functional group through an ester bond.[65] One of the 
advantages to using coumarin as the photo-excitable molecule is that it can be activated in a 
single photon mechanism at 420 nm and in a double photon mechanism at 800 nm which is 
in the near-IR region of the electromagnetic spectrum. Near IR wavelengths of light can pass 
through several centimeters of tissue and can be utilized to affect the release of a drug 
molecule, making the system much promising for use as a real drug-delivery system.   
An alternative method for photon-mediated release of cargo is to use molecules that 
act as impellers to cause fluid flow within the pores and subsequently release the 
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encapsulated guest molecule. Azo derivatives are used extensively in this area as they are 
frequently photo-isomerable at visible wavelengths of light.[66] This area of research is 
largely dominated by the work of Jeff Zink and coworkers, their work in free particles has 
shown that molecules such as benzene and 1,3,5- benzyltrimethoxybenzene  (BTB) can be 
conjugated to an azo linker which results in a material sensitive to 457 nm light.[67] Upon 
exposure to this wavelength of light, the guest molecule (coumarin) can be observed to leave 
the pores of the MS particles. An experiment was carried out in which the photon source was 
switched on and off periodically which resulted in stepwise release of coumarin only when 
the photon source was switched on. Further advances on this system include the replacement 
of azobenzene and azo-BTB impellers with a 4-phenylazoaniline impeller excitable at 413 
nm.[68] The study showed that the anticancer-drug camptothecin would exit the pore upon 
photo-irradiation of cells exposed to the particle system, inducing cell apoptosis. One of the 
advantages to using a nano-impeller system over a photo-cleavable/electron donating system 
is that cis-trans isomerization of azo-bonds works well in aqueous conditions. Photo-
cleavable molecules may or may not work in aqueous systems and is entirely dependent on 
molecular architecture; however those systems that rely on generation and transfer of an 
excited electron often have that excitation mechanism quenched in aqueous media. 
 
 
Figure 11. Schematic diagram of azo-impellers in the pores of MSPs and the type of motion available to the 
molecule during photoisomerization. Reprinted with permission from Lu, J.; Choi, E.; Tamanoi, F.; Zink, J. I., 
Small 2008, 4 (4), 421-426. Copyright 2008 John Wiley & Sons. 
22 
 
Overall there does not seem to be much application of photon-mediated release systems 
within the body, as biological tissue is opaque to visible light wavelengths; however products 
such as slow release sunscreen, acne medication and other topical pharmaceuticals may 
benefit from release systems of this type. 
One of the more quickly expanding areas of MS drug delivery systems are those that 
include some sort of magnetic functionality. In many cases the inclusion of magnetic 
functionality has been shown to provide a way of physically moving or sequestering the 
nanoparticles under static magnetic fields.[69] More relevant to the field of therapeutics is the 
property that when MS-magnetic hybrid systems are placed in a rapidly alternating magnetic 
field, heat is generated through frustration of one of the hypothesized relaxation 
mechanisms.[70] Heating in this fashion, termed magnetic hyperthermia is also an effective 
method for releasing cargo molecules. Chen and coworkers have shown that Fe3O4 
nanoparticles coordinated with a carboxylate terminated linker molecule can successfully 
cleave the linker using heat generated during exposure to a magnetic field.[71] The heat 
caused lyses of the organic linker molecule, allowing the cargo molecule to diffuse from the 
pore. No leaching of cargo molecules was observed in the absence of a magnetic field. One 
of the most recent reports of magnetic MS systems uses Fe2O3 particles embedded in the MS 
matrix, the MS particle is then coated with PNIPAM to form a thermally responsive cap.[72] 
Upon application of an alternating magnetic field, the heat generated causes the polymer cap 
to swell and release the contents of the pores. The system was also heated to 45oC in order to 
cause the swelling of the PNIPAM cap, release of guest molecules in this fashion was 
directly comparable to the amount released under magnetic field. 
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Figure 12. The total release of catalase from magnetic MSPs (blue) and the enzymatic activity of caspase (red). 
Release of caspase from MSP under alternating magnetic field and traditional temperature increases have been 
studied. Reprinted with permission from Baeza, A.; et al., Chemistry of Materials 2012, 24 (3), 517-524. 
Copyright 2012 American Chemical Society.   
Several other methods have been developed to allow controlled drug release from MS 
particles which rely on external stimuli. Electric fields have been used to release guest 
molecules in two different systems; the first used an electrically conducting polymer to cap 
the pores of the particle while the second system employed dipolar molecules under an 
alternating magnetic field as impellers.[73, 74] In the former study MS particle is embedded in 
a polypyrrole film. Upon application of a DC electric field, release of a nerve growth factor is 
increased by almost 2-fold above controls. This increase in released nerve growth factor 
results in an approximately 25% increase in the number of healthy increase in rat adrenal PC-
12 cells. The latter study utilizes cyanophenyl moieties, which possess strong dipolar 
moments along the long axis of the molecule. This attribute allows the molecule to reorient 
itself quickly with an alternating electric field, creating the impeller effect. By applying the 
alternating electric field, a 40% increase in the release of ibuprofen was observed and the 
time for total release could be lowered nearly 25%. Nanoparticle systems utilizing the 
thermo-responsive nature of PNIPAM as a capping strategy have also been reported.[75, 76] In 
both examples, PNIPAM is directly grafted onto the surface of MS particles and the guest 
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molecule release profile is examined at 20oC and 40oC. Both systems show that only slow 
and incomplete leaching of guest molecules occur at 20oC temperature while mixtures in 
40oC solutions demonstrates rapid and almost total release of the guest molecule.  
The last stimulus examined is that of ultrasonication. Depan et al. have shown that 
mesoporous silica can be capped with the biopolymer chitosan to effectively slow the release 
of ibuprofen.[77] The application of ultrasound to particle solutions results in a 2-fold increase 
of ibuprofen release with approximately 75% of the initially loaded drug being released after 
24 hours. This system is not particularly unique, but recent advances in ultrasonic surgery 
techniques means that a system such as the one described above could by introduced prior to 
surgery and entrapped therapeutic molecules released during the procedure. In this way anti-
cancer compounds could potentially be introduced at tumor sites to ensure complete 
eradication of tumor or neuronal growth factors could be employed to facilitate healing of 
nerve tissue and promote differentiation of nerve cells. Indeed a similar system has been 
developed to facilitate surgery in which an MRI contrast agent is entrapped within MSPs and 
is used to guide the ultrasound beam.[78]  
IV. Actively Targeted MSP Systems 
Early research into drug delivery applications of MSPs focuses almost entirely on the 
conveyance of anti-cancer pharmaceuticals. The theoretical impetus for the research being 
that particles carrying anti-cancer pharmaceuticals would achieve greater concentrations in 
cancer cells due to passive endocytotic uptake. This increased uptake is due to the fact that 
cancer cell metabolism is faster than the normal tissue and endocytosis of particles occurs at 
an increased rate in these cell types. However, particles could still be effectively endocytosed 
by non-cancerous cells potentially resulting in some of the same side effects seen with 
traditional oral and intravenous delivery of these pharmaceuticals. To this effect many MSP 
systems have been developed with surface bound targeting ligands to further improve the 
biodistribution of MSPs.[79]  
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Figure 13. This image shows the MRI scan of a gadolinium-based dendritic contrast agent which has been 
functionalized with folate molecules (left side) and left unfunctionalized (right side). The circles represent areas 
of grafted tumors in female mice. The functionalized material shows a much higher contrast in tumors than the 
unfunctionalized gadolinium carrier. Reprinted with permission from Swanson, S. D.; et al., Int. J. 
Nanomedicine; 2008, 3(2), 201 – 210. Copyright 2008 Dovepress   
Folic Acid 
Initial reports of targeted MSP systems used small molecules such folic acid to 
improve endocytotic uptake in cancer cells. Folic acid based targeting of MSPs remains one 
of the most popular methods of showcasing the ability of MSPs to be targeted to specific cell 
types. The first of these studies appeared in 2007 by Pasqua and coworkers.[80] In this work 
MSPs were functionalized with dendritic polyethyleneimine (PEI) molecules and end-capped 
with folic acid (FA). This approach proved successful towards increasing the amount of 
particles that were endocytosed by the MCF and HeLa cancer cell lines under investigation. 
These results were quickly followed by work from the groups of Zink and Dubernet in which 
folic acid functionalized MSPs were found to cause cell death with greater efficiency than 
non-targeted MSPs.[81, 82] 
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Figure 14. Results of cell growth inhibition assay of folate modified MSPs in HFF and PANC-1 cells. Cells 
were treated with bare nanoparticles (NP), camptothecin loaded nanoparticles (CPT-NP), or camptothecin-
loaded folate-functionalized nanoparticles (CPT-FA-NP). Reprinted with permission from Liong, M.; et al., 
ACS Nano 2008, 2 (5), 889-896. Copyright 2008 American Chemical Society.  
Linden et al. published a second report on the PEI-folic acid functionalized MSPs. In 
this study the authors showed that the endocytosis of FA MSPs increased five-fold in HeLa 
cells over the non-cancerous human embryonic kidney 293 cell line. The difference of MSP 
concentrations in the two cell lines is explained as a property of the number of folate 
receptors on the surface of the cells; the HeLa cell line having considerably more FA 
receptors than HEK-293 cells. Linden and coworkers expanded the ability of their PEI-FA 
MSPs to show that they could also carry pharmaceutical molecules into cancer cells, further 
increasing the amount of cell death by approximately 30% over controls (anticancer drug and 
FA-MSP controls).[83]  
In addition to PEI coatings, folic acid has also been employed in MSP systems with 
phospholipid coatings. Wang and coworkers synthesized a hydrophobic MSP and coated the 
particle with folate-PEG conjugate before associating phospholipids with the external surface 
of the particles.[84] Folic acid proved to be an effective targeting agent in HeLa cells when 
compared with untargeted, PEGylated MSPs. Additional studies in A549 cells expressing 
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normal amounts of folate receptors show only 40% of the cell population has endocytosed 
MSPs as compared to 99% of HeLa cells. The study also demonstrates, via FITC-IgG 
conjugate adsorption that PEGylation of MSPs results in lower non-specific protein binding 
than unfunctionalized MSPs. There are no control experiments of MSP-phospholipid 
interactions with cells or endocytosis which are necessary for establishing the nature of the 
interaction between the MSP and the cell. Additionally, the endocytosis data are not backed 
up by a competitive binding assay in which free folic acid is added to the media to bind FA 
receptors and prevent signal-specific endocytosis of MSPs, this test would help to validate 
the precise endocytosis mechanism by which the author’s MSPs enter the cells.   
The groups of Kaskel, Salvetat, Wu and Pasqua have all followed suit and developed 
their own MSP systems that rely on FA to achieve cancer cell specific targeting.[85-88] Kaskel 
et al. synthesize a Fe3O4 nanoparticle around which mesoporous silica was generated. The 
Fe3O4 nanoparticle is hypothesized to allow the MSP system to be targeted via an external 
magnetic field. The pores of the MSPs are then loaded with dox and showed increased ability 
to kill cancer cells; approximately 20% less cell population between free dox and FA 
functionalized MSPs loaded with dox in 24 hours. Salvetat et al. showed that MSPs 
functionalized with folate ligands are endocytosed more effectively than MSPs with a PEG 
coating. However, the effectiveness was not quantified and only the mean fluorescence 
intensity is reported.  
Wu and coworkers have synthesized a system in which dox is linked to the MSP via a 
pH-sensitive hydrazone linker and folic acid is grafted onto the MSP surface to provide 
targeting. In this study the viability of three cell lines (HeLa, L929, A549) was evaluated 
against exposure to free dox, dox-MSPs and FA targeted dox-MSPs. Experimental finding 
clearly indicate that L929 and A549 (FA-negative) cell lines have roughly the same viability 
with either targeted or untargeted MSP systems. In the case of HeLa cells (FA-positive), 
targeted MSPs prove more effective at killing cells than untargeted MSPs, however 
viabilities for both MSP tests are higher than for the control group in which cells are exposed 
to free dox in solution.  The results may be explained in part due to the employment of a 
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MTT assay as the viability measuring experiment and the potential discrepancies as outlined 
in Section II.  
The study performed by Pasqua et al. examined the difference in uptake of folic acid 
modified MSPs between one normal human cell line (HEK293) and two cancer cell lines 
(MCF-7, T47D, and HeLa). The cell lines HEK 293 and MCF-7 are not characterized by an 
overexpression of folate receptors and correspondingly the data involving particle uptake in 
these two lines shows that endocytosis of folate modified and unmodified MSPs are nearly 
identical. While in the two cell lines that do show overexpression of folic acid receptors, 
HeLa and T47D, MSP endocytosis is clearly enhanced for particles modified with folic acid. 
The study also shows that in HEK 293 cells, free camptothecin (Cp) kills the same amount of 
cells as Cp loaded in MSPs, while for HeLa cells, MSP loaded with Cp was much more 
effective at killing cells than free Cp after 24 hours.  
 
Saccharides 
Monosaccharides have also been recognized as being able to direct MSPs to different 
cell types. Mannosylated MSPs first appeared in the literature in 2008 in a study by Park et 
al. on MSP-mediated gene delivery.[89] In this report mannose was covalently attached to a 
polyethyleneimine polymer to allow receptor mediated endocytosis of MSPs in HeLa and 
Raw 264.7 cells (luekaemic monocyte macrophage). Endocytosis of MSPs was quantified by 
examining the amount of DNA delivered to the cells. Surprisingly, mannosylation did not 
result in higher DNA concentrations in HeLa cells while results for Raw 264.7 cells clearly 
showed an increase in DNA concentrations for mannosylated MSPs, especially when the 
polymer to DNA weight ratio was below 10. A competition assay in which Raw 264.7 cells 
were exposed to free mannose in growth media resulted in decreased amount of DNA 
delivered to the target cells. This result indicated that mannose receptor mediated endocytosis 
played a role in increasing the transfection efficiency of the DNA-MSP system.   
The field of saccharide targeting of  MSPs has largely been the domain of Durand and 
coworkers.[90-93] They have utilized mannose in four publications in order to prove the 
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effectiveness of targeted MSPs in cancer research. Their system consists of MSPs 
functionalized with porphyrin or fluorene molecules in order to convert near IR (NIR) 
wavelengths of light to excited electrons which are then transferred to adventitious oxygen, 
resulting in the generation of toxic species (singlet oxygen radicals, peroxides and other 
reactive oxygen species (ROS)) followed by cell death. Initial studies for these systems were 
carried out in MDA-MB-231 breast cancer cells and showed that the combination of NIR 
radiation and mannose-mediated targeted led to the death of all cells in the culture. Control 
experiments from ([90]) show that irradiation did not kill a significant proportion of cells and 
that MSPs alone could only account for 20 – 40% of cell death. In the most recent studies by 
this group, breast cancer cell lines MCF-7 and MDA-MB-231 and colon cancer cells HCT-
116 are treated with fluorene containing MSPs that have covalently grafted mannose on the 
particle surface. The newer system ([92]) shows less toxicity in MDA-MB-231 cells (67% cell 
death as opposed to 100%) although the overall toxicity of the galactosylated MSPs is at least 
20 % greater than MSPs with fluorene alone. In addition, the MSP functionalized with the 
fluorene derived sensitizer has also been tested in vivo on xenografted (HCT-116) mice. 
Excised tumors in mice that received both MSPs and 760 nm laser irradiation were less than 
30% mass of the untreated and MSP only controls. Mice with full treatment also showed no 
metastases in the liver or colon as compared to the control groups in which 50% of 
individuals showed metastases in either the liver or colon.   
A system employing a polysaccharide targeting agent has been developed by the 
group of Durand et al.[93] In this study they use their previously developed porphyrin-based 
photosensitizing MSP coupled with a hyaluronic acid (HA). Human colorectal cancer cells 
(HCT-116), when exposed to MSPs coupled with HA show approximately 30 % and 0 % 
viability after two and three days respectively. This is a 40 % and 30 % decrease in cell 
survival over cells treated with unfunctionalized MSPs or irradiated with NIR laser light 
alone. It should be noted that viability was quantified using the MTT assay so the actual 
values may not be accurate.  
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Figure 15. Confocal images of living HCT-116 colorectal cancer cells incubated with FITC-MSP (A) or FITC-
MSP with targeting galactose (B) in the absence (top row) or presence of free galactose (bottom row, 10 mM). 
Images show the preferential uptake of the galactose targeted MSPs and that endocytosis is dependent on 
receptor mediated endocytosis.  
Though no in vivo studies involving HA polymer and MSP are currently published, 
based on the Durand’s earlier record of publications a study of this nature should not be far 
behind. Hyaluronic acid represents one of the most promising new capping/targeting agents 
in the field of MSP drug delivery devices. This is due to three main factors, first is the role 
that HA plays in tumor progression. Overproduction of hyaluronidase HYAL-1 by cancer 
cells results in the degradation of the extracellular HA matrix. Matrix fragments of HA are 
known to promote angiogenesis and thus tumor growth.[94, 95] Cancer cells also express an 
abundance of CD44 hyaluronan receptors in order to ensure that enough HA is available to 
degrade and continue angiogenesis. The second factor is the ability of HA encapsulated virus 
to escape phagocytosis and avoid activating the immune system.[96] The third factor involves 
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the normally fast turnover rate of HA in a healthy human, approximately one third of the 
total HA per day.[97] All of these attributes have the potential to combine into a drug delivery 
system capable of directed targeting to cancer cells, rapid degradation of the cap which 
would lead to release of any potential cargo and the ability to be rapidly cleared from the 
body by an easily accessible and plentiful degradation pathway.              
   
Small Molecules 
Reports of other MSP systems utilizing small molecules for to engage receptor 
mediated endocytosis mechanisms are currently lacking in the literature. Vivero-Escoto et al. 
have recently developed a system for MRI contrast in which anisamide (AA) is covalently 
bound to a PEG chain and tethered to the MSP surface.[98] Human pancreatic carcinoma cells 
(AsPC-1) are exposed to AA functionalized and unfunctionalized MSPs. Confocal images of 
cells exposed to these nanoparticles were interpreted to have a larger concentration of AA 
functionalized MSPs within the cell bodies than unfunctionalized MSPs. The cell lines 
studied were exposed to particles for 24 hours, removing the possibility of time dependent 
endocytosis as the result of these differences. However these results are said to correspond to 
ICP quantification of Gd in the centrifuged cell pellet, but this data is unavailable in the full 
paper.  
Luo et al. have designed and characterized a targeted MSP in which the collagen, also 
acts as the pore capping agent and the small molecule, lactobionic acid (LA) is the targeting 
molecule.[31] Collagen is linked to the surface of the MSP via a disulfide bond, making the 
cap potentially labile to reducing conditions found in the cell. In this study the authors 
affected the release of the collagen cap via addition of DTT to cell growth media. After the 
addition of collagen, LA was grafted to the matrix on the surface of the MSP. The authors 
then observed an approximate 2-fold increase of cells that endocytosed LA targeted MSPs 
over untargeted control in HepaG2 cells. A second experiment in which the endocytosis of 
targeted MSPs in cancer cells was compared with the uptake in normal cells showed an 
approximate 2-fold increase in the concentration of MSPs in cancer cells. No controls were 
32 
 
available to determine whether the increase in targeted MSP concentration was due to LA or 
due to targeting from RGD fragments native to the collagen matrix. Additionally, collagen is 
a biomolecule well known for activating the immune system and autoimmune response in 
collagen induced arthritis.[99-101] This effect is more pronounced when the source of the 
collagen is foreign to the living system being studied. These factors make the continued use 
of collagen as a capping agent unclear and certainly unadvisable in certain patients until 
careful in vivo studies are carried out to confirm or dispute immune system activation.     
   
DNA, RNA and Antibody Targeting   
  Macromolecular targeting agents, like small molecule targeting agents for cancer 
therapy generally rely on the overexpression of certain cell surface receptors common to 
several cell types to increase endocytosis of MSPs. In contrast DNA, RNA and antibody 
derived targeting moieties can provide an increased level of cell-specific stimuli for 
mediating MSP association and/or endocytosis. This could potentially mean that MSPs 
targeted with DNA, RNA and antibodies could one day be entirely specific for cell type and 
potentially from individual to individual.   
The small peptide RGD is one of the most studied molecules of its kind for affecting 
the endocytosis of MSPs into cancer cells. This is due to the fact that the RGD sequence 
binds with several different types of integrins and can be modified and cyclized to bind to 
specific integrin sequences.[102] While RGD-based targeting abilities have been recognized 
for some time, one of the first comprehensive MSP systems developed to take advantage of 
this was by Cheng et al.[103] In their study, an MSP was developed with a NIR contrast agent 
enabling imaging of the particle and a NIR active palladium porphyrin complex for 
photodynamic therapy. The MSP was evaluated for its ability to kill two cancer cell lines, 
U87MG gioblastoma cells and MCF-7 cells. It was observed that in experiments with 
U87MG cells, known to have an elevated level of α vβ3 integrin receptors, that MSPs with 
RGD functionalization provided excellent toxicity with less than 10% of cells surviving after 
MSP treatment and laser light irradiation. In contrast, MSPs functionalized only with PEG 
33 
 
only destroyed 20 to 30% of cells as compared to the negative control. In MCF-7 cells, RGD 
functionalization proved as effective as PEGylated MSPs resulting in approximately 20 – 
30% cell death as compared to negative control. 
The difference in uptake between primary cancer cells and metastatic cancer cells of 
MSPs functionalized with RGD or transferrin (Tf) was observed and reported by Ferris et 
al.[104] In this work MSPs were either functionalized with cyclic RGD or transferrin and then 
loaded with CPT and evaluated for cell killing ability. In cell lines expressing an abundance 
of Tf receptors (Panc-1 and BT-549) Tf-functionalized MSPs would kill up to 60% of cells. 
 
Figure 16. (A) Gel-electrophoresis of MDA-MB-435 and MCF-7 cells and confocal images (B) of the cells 
having been exposed to FITC-labeled MSPs expressing either folate or cyclic RGD targeting molecules. (C) 
Gel-electrophoresis of HFF, PANc-1 and BT549 cells to confirm the presence of the folate receptor CD71. (D) 
Confocal images of cells having been exposed to FITC labeled MSPs expressing folate or unmodified. Particles 
appear green in panels B and D, the amount of green observed in the micrographs can be roughly correlated 
with the amount of cell-surface receptor found through electrophoresis  
MSPs bearing RGD functionalization would kill up to 50% of cell populations in MDA-MB 
cells. Confocal images of MSPs in cells presents a picture that targeting molecules RGD and 
Tf behave as expected in examined cells lines. However, well quantified results for 
endocytosis efficiencies are not available in this study. 
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In a study by Ashley et al. siRNA was again employed as a therapeutic molecule and 
an MSP supported lipid bilayer with a targeting group, SP94 and an endosomolytic peptide, 
H5WYG.[105] It was observed that siRNA containing MSPs are effective in halting 
production of their target proteins and arresting the cell cycle in the G1/G0 and G2/M phases. 
Furthermore, western blot analysis of cyclin A2 (Appendix A) concentrations revealed that 
siRNA loaded MSPs do not target healthy liver cells but do target and effectively decrease 
cyclin A2 concentrations in Hep3B liver carcinoma cells. Analysis of apoptosis markers also 
confirms this,  100% of Hep3B liver carcinoma cells are positive for apoptosis markers while 
less than 10% of normal liver cells express these markers after the same time period. A study 
of annexin V and PI concentrations in Hep3B and normal hepatocytes after exposure to 
targeted siRNA lipid bilayer protocells or lipid bilayer MSPs reveals that protocells are still 
better at targeting and killing Hep3B cells while leaving the normal cells undamaged. 
In a 2009 study by Zhu and coworkers reported an MSP system functionalized with 
polyelectrolyte monolayers and a cancer cell specific DNA aptamer for cellular targeting.[106] 
The aptamer was shown to effectively increase toxicity of the MSP system in HeLa cells 
which express the receptor. A second cell line QGY 7703, to which the aptamer is not 
targeted did show doxorubicin related toxicity, but no more than the control experiment in 
which MSPs were loaded with dox absent of the aptamer. While the amount of HeLa cells 
killed by targeted MSPs was given as 58% versus control, this is only 30% greater than 
untargeted MSPs, indicating that even though the targeting molecule is specific for one cell 
type; other types of endocytosis are available for access by the MSP. This is especially 
evident in the studies of QGY 7703 studies in which both targeted and untargeted MSPs 
killed approximately 40% of the control cell populations.    
 
V. Analytical Applications 
In addition to their ability to deliver drugs directly to cells of interest, MSPs have also 
been developed to aid in the analysis of diseases, contrast agents, and for biochemical 
separations. Many of the systems described here are multi-function in that they combine 
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several of the attributes previously discussed e.g. controlled release and targeting with some 
new functionality conferring analytical importance to the MSP. Indeed, it should be seen as 
necessity for any successful MSP based analytical system to have clearly defined roles for all 
of the easily accessible areas of the particle, external surface area, internal (pore) surface 
area, and pore volume. Biochemical separations with MSPs may be excluded from such 
criteria, however a different set of criteria such as the need for tightly controlling 
locality/density of functional groups and physical parameters of the particles like pore size, 
pore volume, and framework stability.  
Separations 
In the field of biochemical separations, there are two reasons why MSPs stand out, 
the first is the ability to selectively sequester biomolecules based on their size in the pores 
and the second is the ease at which functional groups can be added to the particle, either 
through post-synthesis grafting or in-situ co-condensation techniques. These attributes allow 
MSPs to sequester a large number of proteins of a particular size and to increase protein 
loading and orientation through addition of functional groups on the MSP.  In a recent study, 
Fan et al. utilized SBA-15 type (8 nm pore) MSPs for the sequestration and proteolysis of 
myoglobin.[107] Trypsin digest of proteins is a common method for developing a protein 
“fingerprint” of molecular fragments having different masses however this method suffers 
from problems related to incomplete digests and extended reaction times. Experiments in this 
study show that all myoglobin was rapidly sequestered and subsequent digestion with trypsin 
occurred without protein leaching. Additionally, it was observed by the authors of this study 
that proteolysis occurred in approximately 10 minutes in myoglobin entrapped in MSP as 
compared to 12 hours for digestion in solution. The samples digested in MSPs also had equal 
or higher sequence coverage than solution digested samples. This implies that proteolysis 
occurs only at specific areas when proteins are in MSPs, generating fewer unidentifiable 
fragments as opposed to solution experiments. The authors cite previous, unpublished works 
in which the surface of a different MSP system was able to unfold a target protein which 
caused the efficiency of digestion to increase in that study as well. One other interesting 
experiment showed that different types of surface (calcined, extracted, functional groups) 
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were evaluated for their sequestration and digestion abilities. Acid extracted MSPs and the 
acid extracted thiol-functionalized MSPs had a two-fold increase in the occurrence of protein 
sequence matching over controls.  
A second example of biomolecular separation with MSPs comes from the group of 
Zou et al.[108] In this study MSPs were functionalized with titanium phosphonate for the 
selective enrichment of phosphorylated peptides. Specific phosphorylation events due to 
cancer metabolism can be detected in the bloodstream, so effective enrichment of these 
phosphorylated peptides by MSPs may potentially be utilized to detect cancer with a simple 
serum screening. In model experiments, the authors clearly show that titanium MSPs (Ti-
MSPs) will selectively adsorb only the phosphorylated peptide sequences of β-casein and 
fibrinogen. The results of MALDI-TOFMS showed clean spectra with only phosphorylated  
 
Figure 17. Analysis of protein in human blood serum by MALDI-TOF. The results in panel (C) show the mass-
spec analysis of unpurified blood serum while the results from panel (D) show only those phosphorylated 
proteins present in the blood serum sample. Reprinted with permission from Hu, L.; et al., Analytical 
Chemistry; 2009, 81 (1), 94-104. Copyright 2009 American Chemical Society. 
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peptide peaks present. A second study was carried out in which blood from humans with 
heptacellular carcinoma (HCC) and healthy individuals (HI) was subjected to MSP 
sequestration and MALDI-TOFMS in order to determine if significant differences in protein 
concentrations could be observed. The results of this study clearly showed a difference in 
concentrations of four different phosphorylated peptides between of HCC and HI test 
populations. While this system may not have detected all available phosphorylated 
biomarkers; the fact that significantly varying peptide concentrations were observed from the 
mixture of human serum is excellent proof of concept.  
  A third study in which pore size, surface functionalization and particle type was 
varied to determine the best system for protein enrichment of blood plasma and urine was 
carried out by Terracciano et al.[109] This study looks at the protein profiles captured from 
human plasma and urine in order to develop the most effective MSP for the sample 
conditions. All of the MSPs examined in this work were found to be capable of significantly 
enriching the protein contents of urine and plasma, however MSPs functionalized with 
aminopropyl (AP) groups excelled in plasma studies while tetraacetic acid diethylamine 
(TED) functionalized material were better at enriching urine protein. Both AP and TED 
functionalized MSPs were able to increase the number of detected peaks from approximately 
a dozen in controls to over 160 (plasma) and 199 (urine) respectively. Reproducibility 
analysis showed that while m/z values were highly consistent between experiments, and 
though the peaks heights varied by as much as 33% for some peptide sequences, the overall 
variance was less than 15% for all tested MSPs. 
 Imaging Agents 
During the course of the previous decade numerous reports of MSP-based imaging 
agents have been published. Imaging studies using MSPs have tended to fall into two 
categories, MRI contrast agents and NIR imaging agents. Many systems also tout the ability 
to be detected via particle fluorescence, however fluorescence imaging is really only 
applicable in cell culture or tumor-grafted mice as the penetration depth of visible light is less 
than 10 mm and MSPs bearing only visible-spectrum fluorescent reports are not considered 
here (though these systems may be employed in biopsy).[110, 111] Similar to drug delivery 
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devices, MSPs can potentially be targeted to specific cell types which can lead to the 
detection or confirmation of disease, the majority of current work of this type is designed for 
tumor imaging. Also similar to drug delivery devices, active targeting would theoretically 
lower the concentration of imaging agent needed in a given patient. Protection from the 
biological environment and clearance conferred by capped pores may also allow for longer 
half lives of imaging agents. The pores of MSPs used for imaging are often at least partially 
empty allowing future systems the ability to carry therapeutic molecules, once again, in those 
systems where the therapy/imaging combination is carried out, the work is done in tumor 
cells.  
A system developed by Gianotti et al. was shown to be effective in carrying a NIR-
active molecule into cells and protect the imaging molecule from degradation in the 
lysosome.[112] An aggregate-producing synthesis for MSPs from fumed silica was utilized 
resulting in 100 – 300 nm clusters which were subsequently loaded with the imaging agent, 
IRIS3. The clusters were then ultrasonicated to produce particles between 2 and 20 nm. 
Despite the lack of covalent attachment between the IRIS3 and the silica framework, the 
material was observed to retain fluorescence for 24 hours while exposed to cells. This 
indicates that no leaching of IRIS3 was observed even after 24 hours exposure to cellular 
environments. Additionally, IRIS3 was protected from the degradation processes in the 
lysosome by the pores of the MSPs. The MSPs were observed to accumulate in the lysosome 
and neither acidic pH nor neutral pH of chloroquine treated lysosomes had any effect on the 
fluorescence of the IRIS3.  
A second system to utilize the NIR end of the spectrum employs gold nanorods 
instead of small photoactive molecules.[113] Utilization of MSPs to carry gold nanorods 
(GNs) helps to remove several of the problems associated with gold nanoparticles including 
low particle stability and high cytotoxicity. In order to remediate problems related to 
stability, GNs are routinely coated in cetyltrimethylammonium bromide, which is known to 
be extremely toxic in and of itself and does not form stable small assemblies at lysosomal pH 
(4.0 - 5.0). The synthesis of the gold-MSP material by Zan et al. results in monodisperse GNs 
surrounded by mesoporous silica coatings. The design of this system provides three 
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improvements; the first is stability as the GNs are now surrounded by a robust silica shell and 
protected from the environment. The second improvement results in improved extinction 
coefficient due to the fact that GNs encased in silica can no longer participate in self-
quenching events. The last advantage is strinking increase of biocompatibility of GN-MSPs 
over the CTAB-GNs. In order to prove that imaging ability is not lost upon functionalization 
of the silica network, antibodies were conjugated to the particles using electrostatic 
interactions and then the antibody-GN-MSP system was tested in MCF-7 breast cancer cells. 
The results of this study show that GNs may be targeted to specific cell types and can then be 
used to generate an image using localized surface plasmon resonance. 
 
Figure 18. Dark field images of MCF cells without treatment (a), treated with GN-MSPs (b), treated with anti-
HER2-conjugated GN-MSPs (positive targeting ligand) (c), and anti-CEA8-conjugated GN-MSPs (negative 
targeting ligand) (d). The GN-MSP composites appear red in the images. Reprinted with permission from He, 
Q.; et al., Nanotechnology 2010, 21 (5), 055704. Copyright 2010 IOP Science.  
The imaging technique garnering the most attention from MSP researchers over the past 
decade is MRI. One of the first accounts of MRI capable MSPs was published in 2004 by the 
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group of Mou et al.[114] In this study gadolinium atoms were incorporated directly into the 
framework of the MSP (Gd-MSP) as evidenced by the lack of crystalline peaks in wide angle 
powder X-ray diffraction experiments and TEM images. The system was to provide 
enhanced contrast over the currently used gadolinium diethyltriammine pentaacetic acid (Gd-
DTPA). By increasing the concentration of Gd-MSPs, the solid supported system proved to 
be more effective at providing contrast for T1 and T2 relaxivities than Gd-DTPA at similar 
concentrations (concentrations were recorded in terms of Gd present). Mou et al. followed 
their first publication with one for another MRI contrast agent based on Fe3O4 particles 
embedded in the MSP framework.[115] The relaxation time for Fe3O4 embedded in MSP is   r2 
= 153 mM-1 s-1, this nearly doubles the r2 = 82.3 mM-1 s-1 value for Gd-MSPs that was 
observed in their earlier work. In 2007, Mou collaborated with D.-M. Huang of the Center 
for Nanomedicine Research in Taiwan for an in vivo study of MSPs functionalized with Gd- 
coordinated DTPA.[116] While this system had smaller r1 and r2 values than the Gd-MSP 
original developed, the measured r1 = 23 mM-1 s-1 and r2 = 34 mM-1 s-1 which are respectively  
5 and 8 times higher than Gd-DTPA by itself. The author’s also demonstrated the long term 
biocompatibility and imaging ability of the MSP system by exposing human mesenchymal 
stem cells (hMSCs) to Gd-DTPA-MSPs. In one study the hMSCs are placed in media with 
specific growth factors and the cells can be observed to properly differentiate. The second 
study involving hMSCs showed that cells exposed to Gd-DTPA-MSPs and injected into a 
mouse brain still demonstrated contrast imparted by the MSP system after 14 days. 
Importantly, no migration of Gd-DTPA-MSPs away from the tumor site was observed.   
 
Figure 19. Images show the brain of a single mouse at 0 days (a), 7 days (b), and 14 days (c) post injection with 
Gd-DTPA-MSP. The arrow indicates the site of particle injection, contrast from the MSP system is still visible 
14 days post injection and has not migrated. Reprinted with permission from Hsiao, J.-K.; et al., Small 2008, 4 
(9), 1445-1452. Copyright 2008 John Wiley & Sons. 
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VI. Conclusion    
Mesoporous silica particles represent one of the most variable material frameworks 
currently being researched. The ability to functionalize the surface of the MSPs with a vast 
array of different organic and inorganic molecules allows for MSPs to be utilized in an 
almost equally vast number of applications. One of the most important applications of MSPs 
and one of the hottest research areas are biological applications for specific disease therapy. 
Recent advances in the literature have begun to move MSPs away from proof-of-concept 
studies and more towards the clinical evaluation of MSPs in vivo for an actual therapy or 
imaging device. This coupled with recent reports on the toxicity of nanoparticles in general 
increases the importance for researchers seeking to do serious evaluations of their MSPs 
biocompatibility to rely on a single well-accepted set of criteria. In addition to criteria for 
biological applications, the parallel review by Haynes and coworkers outlines necessary 
parameters for the physical properties of the MSPs being used to affect change biological 
systems. These events indicate the maturation of MSP research from scientific hypothesis to 
technological proposal, as such our methods and criteria for MSP evaluation must now move 
from bench-top criteria to clinical criteria. 
VII. References    
[1] Y.-S. Lin, K. R. Hurley, C. L. Haynes The Journal of Physical Chemistry Letters. 2012, 3, 364-374. 
[2] E. S. Reich Nature. 2011, 480, 160 - 161. 
[3] J. W. Card, T. S. Jonaitis, S. Tafazoli, B. A. Magnuson Critical Reviews in Toxicology. 2011, 41, 20 - 
49. 
[4] Y. Song, X. Li, X. Du European Respiratory Journal. 2009, 34, 559-567. 
[5] N. Gilbert Nature. 2009, 460, 937. 
[6] B. Fadeel, A. E. Garcia-Bennett Advanced Drug Delivery Reviews. 2009, 62, 362-374. 
[7] N. Lewinski, V. Colvin, R. Drezek Small. 2008, 4, 26-49. 
[8] T. Laaksonen, H. Santos, H. Vihola, J. Salonen, J. Riikonen, T. Heikkilä, L. Peltonen, N. Kumar, D. Y. 
Murzin, V.-P. Lehto, J. Hirvonen Chemical Research in Toxicology. 2007, 20, 1913-1918. 
[9] M. Fisichella, H. Dabboue, S. Bhattacharyya, M.-L. Saboungi, J.-P. Salvetat, T. Hevor, M. Guerin 
Toxicology in Vitro. 2009, 23, 697-703. 
[10] T. Heikkilae, H. A. Santos, N. Kumar, D. Y. Murzin, J. Salonen, T. Laaksonen, L. Peltonen, J. 
Hirvonen, V.-P. Lehto European Journal of Pharmaceutics and Biopharmaceutics. 2010, 74, 483-494. 
[11] M. Al Shamsi, M. T. Al Samri, S. Al-Salam, W. Conca, S. Shaban, S. Benedict, S. Tariq, A. V. 
Biradar, H. S. Penefsky, T. Asefa, A.-K. Souid Chemical Research in Toxicology. 2010, 23, 1796-1805. 
[12] X. Huang, X. Teng, D. Chen, F. Tang, J. He Biomaterials. 2010, 31, 438-448. 
42 
 
[13] Q. He, Z. Zhang, Y. Gao, J. Shi, Y. Li Small. 2009, 5, 2722-2729. 
[14] A. V. Delgado, F. González-Caballero, R. J. Hunter, L. K. Koopal, J. Lyklema Journal of Colloid and 
Interface Science. 2007, 309, 194-224. 
[15] H. Zhang, T. Xia, H. Meng, M. Xue, S. George, Z. Ji, X. Wang, R. Liu, M. Wang, B. France, R. Rallo, 
R. Damoiseaux, Y. Cohen, K. A. Bradley, J. I. Zink, A. E. Nel ACS Nano. 2011, 5, 2756-2769. 
[16] S. P. Hudson, R. F. Padera, R. Langer, D. S. Kohane Biomaterials. 2008, 29, 4045-4055. 
[17] T. Liu, L. Li, X. Teng, X. Huang, H. Liu, D. Chen, J. Ren, J. He, F. Tang Biomaterials. 2011, 32, 1657-
1668. 
[18] J. Lu, M. Liong, Z. Li, J. I. Zink, F. Tamanoi Small. 2010, 6, 1794-1805. 
[19] X. Huang, L. Li, T. Liu, N. Hao, H. Liu, D. Chen, F. Tang ACS Nano. 2011, 5, 5390-5399. 
[20] Q. He, Z. Zhang, F. Gao, Y. Li, J. Shi Small. 2011, 7, 271-280. 
[21] E. Zuccato, D. Calamari, M. Natangelo, R. Fanelli The Lancet. 2000, 355, 1789-1790. 
[22] E. E. Agency in Pharmaceuticals in the Environment, Vol.  (Ed.^Eds.: Editor), Office for Official 
Publications of the European Communities, City, 2010, pp.1-33. 
[23] V. S.-Y. Lin, C.-Y. Lai, S. Jeftinija, D. M. Jeftinija in Capped mesoporous silicates for drug delivery, 
Vol.  (Ed.^Eds.: Editor), (Iowa State University Research Foundation, Inc., USA). City, 2005, pp.129 
pp. 
[24] Y. Cho, R. Shi, A. Ivanisevic, R. Borgens in A mesoporous drug delivery system using an 
electrically conductive polymer, Vol.  (Ed.^Eds.: Editor), (Purdue Research Foundation, USA). City, 
2010, pp.27pp. 
[25] C.-Y. Lai, G. Trewyn Brian, M. Jeftinija Dusan, K. Jeftinija, S. Xu, S. Jeftinija, S. Y. Lin Victor Journal 
of the American Chemical Society. 2003, 125, 4451-4459. 
[26] D. R. Radu, C.-Y. Lai, K. Jeftinija, E. W. Rowe, S. Jeftinija, V. S. Y. Lin Journal of the American 
Chemical Society. 2004, 126, 13216-13217. 
[27] S. Giri, B. G. Trewyn, M. P. Stellmaker, V. S. Y. Lin Angewandte Chemie, International Edition. 
2005, 44, 5038-5044. 
[28] P. Monostori, G. Wittmann, E. Karg, S. Túri Journal of Chromatography B. 2009, 877, 3331-3346. 
[29] H. Kim, S. Kim, C. Park, H. Lee, H. J. Park, C. Kim Advanced Materials (Weinheim, Germany). 
2010, 22, 4280-4283. 
[30] M. W. Ambrogio, T. A. Pecorelli, K. Patel, N. M. Khashab, A. Trabolsi, H. A. Khatib, Y. Y. Botros, J. 
I. Zink, J. F. Stoddart Org. Lett. 2010, 12, 3304-3307. 
[31] Z. Luo, K. Cai, Y. Hu, L. Zhao, P. Liu, L. Duan, W. Yang Angew. Chem., Int. Ed. 2011, 50, 640-643, 
S640/641-S640/648. 
[32] R. Mortera, J. Vivero-Escoto, I. I. Slowing, E. Garrone, B. Onida, V. S. Y. Lin Chemical 
Communications (Cambridge, United Kingdom). 2009, 3219-3221. 
[33] R. Liu, Y. Zhang, P. Feng J. Am. Chem. Soc. 2009, 131, 15128-15129. 
[34] A. M. Sauer, A. Schlossbauer, N. Ruthardt, V. Cauda, T. Bein, C. Braeuchle Nano Letters, 10, 
3684-3691. 
[35] X. Wan, D. Wang, S. Liu Langmuir, 26, 15574-15579. 
[36] J. A. Gruenhagen, C.-Y. Lai, D. R. Radu, V. S. Y. Lin, E. S. Yeung Appl. Spectrosc. 2005, 59, 424-
431. 
[37] Z. Luo, K. Cai, Y. Hu, L. Zhao, P. Liu, L. Duan, W. Yang Angewandte Chemie, International Edition. 
2011, 50, 640-643, S640/641-S640/648. 
[38] A. Patel, P. Heussen, J. Hazekamp, K. P. Velikov Soft Matter. 2011, 7, 8549-8555. 
[39] L. Zhao, J. Ding, P. He, C. Xiao, Z. Tang, X. Zhuang, X. Chen Journal of Controlled Release. 2011, 
152, Supplement 1, e184-e186. 
43 
 
[40] A. Rivinoja, N. Kokkonen, I. Kellokumpu, S. Kellokumpu J. Cell. Physiol. 2006, 208, 167-174. 
[41] F. McCarty Mark, J. Whitaker Altern Med Rev. 2010, 15, 264-272. 
[42] R. V. Benjaminsen, H. Sun, J. R. Henriksen, N. M. Christensen, K. Almdal, T. L. Andresen ACS 
Nano. 2011, 5, 5864-5873. 
[43] Y.-J. Yang, X. Tao, Q. Hou, Y. Ma, X.-L. Chen, J.-F. Chen Acta Biomaterialia, 6, 3092-3100. 
[44] H. Meng, M. Liong, T. Xia, Z. Li, Z. Ji, J. I. Zink, A. E. Nel ACS Nano. 2010, 4, 4539-4550. 
[45] R. Casasus, M. D. Marcos, R. Martinez-Manez, J. V. Ros-Lis, J. Soto, L. A. Villaescusa, P. Amoros, 
D. Beltran, C. Guillem, J. Latorre Journal of the American Chemical Society. 2004, 126, 8612-8613. 
[46] B. Chang, X. Sha, J. Guo, Y. Jiao, C. Wang, W. Yang J. Mater. Chem. 2011, 21, 9239-9247. 
[47] C.-H. Lee, L.-W. Lo, C.-Y. Mou, C.-S. Yang Advanced Functional Materials. 2008, 18, 3283-3292. 
[48] Q. Gan, X. Lu, Y. Yuan, J. Qian, H. Zhou, X. Lu, J. Shi, C. Liu Biomaterials. 2011, 32, 1932-1942. 
[49] J. Gu, S. Su, Y. Li, Q. He, J. Zhong, J. Shi Journal of Physical Chemistry Letters. 2010, 1, 3446-3450. 
[50] T.-W. Kim, I. I. Slowing, P.-W. Chung, V. S.-Y. Lin ACS Nano. 2010, 5, 360-366. 
[51] G. Sun, Y. Chang, S. Li, Q. Li, R. Xu, J. Gu, E. Wang Dalton transactions (Cambridge, England 
2003). 2009, 4481-4487. 
[52] H. S. Park, C. W. Kim, H. J. Lee, J. H. Choi, S. G. Lee, Y.-P. Yun, I. C. Kwon, S. J. Lee, S. Y. Jeong, S. 
C. Lee Nanotechnology. 2010, 21, 225101/225101-225101/225109, S225101/225101-
S225101/225103. 
[53] H. Meng, M. Xue, T. Xia, Y.-L. Zhao, F. Tamanoi, J. F. Stoddart, J. I. Zink, A. E. Nel Journal of the 
American Chemical Society, 132, 12690-12697. 
[54] Y.-L. Zhao, Z. Li, S. Kabehie, Y. Y. Botros, J. F. Stoddart, J. I. Zink Journal of the American Chemical 
Society. 2010, 132, 13016-13025. 
[55] C.-H. Lee, S.-H. Cheng, I. P. Huang, S. Souris Jeffrey, C.-S. Yang, C.-Y. Mou, L.-W. Lo Angewandte 
Chemie (International ed. in English). 2010, 49, 8214-8219. 
[56] J. Yan, G. Springsteen, S. Deeter, B. Wang Tetrahedron. 2004, 60, 11205-11209. 
[57] P. J. Duggan, D. A. Offermann Tetrahedron. 2009, 65, 109-114. 
[58] K. Patel, S. Angelos, W. R. Dichtel, A. Coskun, Y.-W. Yang, J. I. Zink, J. F. Stoddart Journal of the 
American Chemical Society. 2008, 130, 2382-2383. 
[59] A. Bernardos, E. Aznar, M. D. Marcos, R. Martinez-Manez, F. Sancenon, J. Soto, J. M. Barat, P. 
Amoros Angewandte Chemie, International Edition. 2009, 48, 5884-5887, S5884/5881-S5884/5887. 
[60] A. Bernardos, L. Mondragon, E. Aznar, M. D. Marcos, R. Martinez-Manez, F. Sancenon, J. Soto, J. 
M. Barat, E. Perez-Paya, C. Guillem, P. Amoros ACS Nano. 2010, 4, 6353-6368. 
[61] J. Liu, X. Du, X. Zhang Chemistry--A European Journal. 2010, 17, 810-815, S810/811-S810/816. 
[62] T. D. Nguyen, K. C. F. Leung, M. Liong, Y. Liu, J. F. Stoddart, J. I. Zink Advanced Functional 
Materials. 2007, 17, 2101-2110. 
[63] J. L. Vivero-Escoto, I. I. Slowing, C.-W. Wu, V. S. Y. Lin Journal of the American Chemical Society. 
2009, 131, 3462-3463. 
[64] G. Han, C.-C. You, B.-j. Kim, R. S. Turingan, N. S. Forbes, C. T. Martin, V. M. Rotello Angewandte 
Chemie International Edition. 2006, 45, 3165-3169. 
[65] Q. Lin, Q. Huang, C. Li, C. Bao, Z. Liu, F. Li, L. Zhu Journal of the American Chemical Society, 132, 
10645-10647. 
[66] E. Luboch, R. Bilewicz, M. Kowalczyk, E. Wagner-Wysiecka, J. F. Biernat Adv. Supramol. Chem. 
2003, 9, 71-162. 
[67] S. Angelos, E. Choi, F. Vögtle, L. De Cola, J. I. Zink The Journal of Physical Chemistry C. 2007, 111, 
6589-6592. 
[68] J. Lu, E. Choi, F. Tamanoi, J. I. Zink Small. 2008, 4, 421-426. 
44 
 
[69] S. Laurent, D. Forge, M. Port, A. Roch, C. Robic, L. Vander Elst, R. N. Muller Chemical Reviews. 
2008, 108, 2064-2110. 
[70] R. H. a. S. D. a. R. M. a. M. Zeisberger Journal of Physics: Condensed Matter. 2006, 18, S2919. 
[71] P.-J. Chen, S.-H. Hu, C.-S. Hsiao, Y.-Y. Chen, D.-M. Liu, S.-Y. Chen J. Mater. Chem. 2011, 21, 2535-
2543. 
[72] A. Baeza, E. Guisasola, E. Ruiz-Hernández, M. Vallet-Regí Chemistry of Materials. 2012, 24, 517-
524. 
[73] Y. Cho, R. Shi, A. Ivanisevic, R. B. Borgens Nanotechnology. 2009, 20, 275102/275101-
275102/275112. 
[74] Y. Zhu, H. Liu, F. Li, Q. Ruan, H. Wang, M. Fujiwara, L. Wang, G. Q. Lu Journal of the American 
Chemical Society, 132, 1450-1451. 
[75] Y. Yang, X. Yan, Y. Cui, Q. He, D. Li, A. Wang, J. Fei, J. Li Journal of Materials Chemistry. 2008, 18, 
5731-5737. 
[76] Y. Zhu, S. Kaskel, T. Ikoma, N. Hanagata Microporous and Mesoporous Materials. 2009, 123, 
107-112. 
[77] D. Depan, L. Saikia, R. P. Singh Macromolecular Symposia, 287, 80-88. 
[78] Y. Chen, H. Chen, Y. Sun, Y. Zheng, D. Zeng, F. Li, S. Zhang, X. Wang, K. Zhang, M. Ma, Q. He, L. 
Zhang, J. Shi Angewandte Chemie International Edition. 2011, 50, 12505-12509. 
[79] Y.-W. Yang MedChemComm. 2011, 2, 1033-1049. 
[80] L. Pasqua, C. Morelli, F. Testa, D. Sisci, E. Brunelli, R. Aiello, S. Ando, J. B. Nagy Studies in Surface 
Science and Catalysis. 2007, 170B, 1956-1962. 
[81] M. Liong, J. Lu, M. Kovochich, T. Xia, S. G. Ruehm, A. E. Nel, F. Tamanoi, J. I. Zink ACS Nano. 
2008, 2, 889-896. 
[82] V. Lebret, L. Raehm, J.-O. Durand, M. Smaihi, M. H. V. Werts, M. Blanchard-Desce, D. Methy-
Gonnod, C. Dubernet Journal of Sol-Gel Science and Technology. 2008, 48, 32-39. 
[83] J. M. Rosenholm, E. Peuhu, L. T. Bate-Eya, J. E. Eriksson, C. Sahlgren, M. Linden Small. 2010, 6, 
1234-1241. 
[84] L.-S. Wang, L.-C. Wu, S.-Y. Lu, L.-L. Chang, I. T. Teng, C.-M. Yang, J.-a. A. Ho ACS Nano. 2010, 4, 
4371-4379. 
[85] Y. Zhu, Y. Fang, S. Kaskel J. Phys. Chem. C. 2010, 114, 16382-16388. 
[86] M. Fisichella, H. Dabboue, S. Bhattacharyya, G. Lelong, M.-L. Saboungi, F. Warmont, P. Midoux, 
C. Pichon, M. Guerin, T. Hevor, J.-P. Salvetat Journal of Nanoscience and Nanotechnology. 2010, 10, 
2314-2324. 
[87] J. Fan, G. Fang, X. Wang, F. Zeng, Y. Xiang, S. Wu Nanotechnology. 2011, 22, 455102/455101-
455102/455111, S455102/455101-S455102/455117. 
[88] C. Morelli, P. Maris, D. Sisci, E. Perrotta, E. Brunelli, I. Perrotta, M. L. Panno, A. Tagarelli, C. 
Versace, M. F. Casula, F. Testa, S. Ando, J. B. Nagy, L. Pasqua Nanoscale. 2011, 3, 3198-3207. 
[89] I. Y. Park, I. Y. Kim, M. K. Yoo, Y. J. Choi, M.-H. Cho, C. S. Cho International Journal of 
Pharmaceutics. 2008, 359, 280-287. 
[90] D. Brevet, M. Gary-Bobo, L. Raehm, S. Richeter, O. Hocine, K. Amro, B. Loock, P. Couleaud, C. 
Frochot, A. Morere, P. Maillard, M. Garcia, J.-O. Durand Chem. Commun. (Cambridge, U. K.). 2009, 
1475-1477. 
[91] O. Hocine, M. Gary-Bobo, D. Brevet, M. Maynadier, S. Fontanel, L. Raehm, S. Richeter, B. Loock, 
P. Couleaud, C. Frochot, C. Charnay, G. Derrien, M. Smaihi, A. Sahmoune, A. Morere, P. Maillard, M. 
Garcia, J.-O. Durand International Journal of Pharmaceutics. 2010, 402, 221-230. 
45 
 
[92] M. Gary-Bobo, Y. Mir, C. Rouxel, D. Brevet, I. Basile, M. Maynadier, O. Vaillant, O. Mongin, M. 
Blanchard-Desce, A. Morere, M. Garcia, J.-O. Durand, L. Raehm Angew. Chem., Int. Ed. 2011, 50, 
11425-11429, S11425/11421-S11425/11417. 
[93] M. Gary-Bobo, O. Hocine, D. Brevet, M. Maynadier, L. Raehm, S. Richeter, V. Charasson, B. 
Loock, A. Morère, P. Maillard, M. Garcia, J.-O. Durand International Journal of Pharmaceutics. 2012, 
423, 509-515. 
[94] A. L. Raines, M. Sunwoo, A. A. Gertzman, K. Thacker, R. E. Guldberg, Z. Schwartz, B. D. Boyan 
Journal of Biomedical Materials Research Part A. 2011, 96A, 575-583. 
[95] A. Benitez, T. J. Yates, L. E. Lopez, W. H. Cerwinka, A. Bakkar, V. B. Lokeshwar Cancer Research. 
2011, 71, 4085-4095. 
[96] M. R. Wessels, A. E. Moses, J. B. Goldberg, T. J. DiCesare Proceedings of the National Academy 
of Sciences. 1991, 88, 8317-8321. 
[97] S. Robert European Journal of Cell Biology. 2004, 83, 317-325. 
[98] J. L. Vivero-Escoto, K. M. L. Taylor-Pashow, R. C. Huxford, J. Della Rocca, C. Okoruwa, H. An, W. 
Lin, W. Lin Small. 2011, 7, 3519-3528. 
[99] D. D. Brand, K. A. Latham, E. F. Rosloniec Nat. Protocols. 2007, 2, 1269-1275. 
[100] C. Chunxia, Z. Peng, P. Huifang, R. Hanli, H. Zehua, W. Jizhou Journal of Ethnopharmacology. 
2011, 133, 573-582. 
[101] M. G. Patino, M. E. Neiders, S. Andreana, B. Noble, R. E. Cohen Journal of Periodontal 
Research. 2003, 38, 458-464. 
[102] E. Ruoslahti Annual Review of Cell and Developmental Biology. 1996, 12, 697-715. 
[103] S.-H. Cheng, C.-H. Lee, M.-C. Chen, J. S. Souris, F.-G. Tseng, C.-S. Yang, C.-Y. Mou, C.-T. Chen, L.-
W. Lo J. Mater. Chem. 2010, 20, 6149-6157. 
[104] D. P. Ferris, J. Lu, C. Gothard, R. Yanes, C. R. Thomas, J.-C. Olsen, J. F. Stoddart, F. Tamanoi, J. I. 
Zink Small. 2011, 7, 1816-1826. 
[105] C. E. Ashley, E. C. Carnes, G. K. Phillips, D. Padilla, P. N. Durfee, P. A. Brown, T. N. Hanna, J. Liu, 
B. Phillips, M. B. Carter, N. J. Carroll, X. Jiang, D. R. Dunphy, C. L. Willman, D. N. Petsev, D. G. Evans, 
A. N. Parikh, B. Chackerian, W. Wharton, D. S. Peabody, C. J. Brinker Nature Materials. 2011, 10, 
389-397. 
[106] C.-L. Zhu, X.-Y. Song, W.-H. Zhou, H.-H. Yang, Y.-H. Wen, X.-R. Wang Journal of Materials 
Chemistry. 2009, 19, 7765-7770. 
[107] J. Fan, W. Shui, P. Yang, X. Wang, Y. Xu, H. Wang, X. Chen, D. Zhao Chemistry--A European 
Journal. 2005, 11, 5391-5396. 
[108] L. Hu, H. Zhou, Y. Li, S. Sun, L. Guo, M. Ye, X. Tian, J. Gu, S. Yang, H. Zou Analytical Chemistry 
(Washington, DC, United States). 2009, 81, 94-104. 
[109] R. Terracciano, L. Pasqua, F. Casadonte, S. Frasca, M. Preiano, D. Falcone, R. Savino 
Bioconjugate Chemistry. 2009, 20, 913-923. 
[110] J. P. Celli, B. Q. Spring, I. Rizvi, C. L. Evans, K. S. Samkoe, S. Verma, B. W. Pogue, T. Hasan 
Chemical Reviews. 2010, 110, 2795-2838. 
[111] C. Ran, Z. Zhang, J. Hooker, A. Moore Molecular Imaging and Biology, 1-7. 
[112] E. Gianotti, C. A. Bertolino, C. Benzi, G. Nicotra, G. Caputo, R. Castino, C. Isidoro, S. Coluccia 
ACS Applied Materials & Interfaces. 2009, 1, 678-687. 
[113] Q. Z. a. J. Q. a. X. L. a. S. He Nanotechnology. 2010, 21, 055704. 
[114] Y.-S. Lin, Y. Hung, J.-K. Su, R. Lee, C. Chang, M.-L. Lin, C.-Y. Mou Journal of Physical Chemistry B. 
2004, 108, 15608-15611. 
46 
 
[115] Y.-S. Lin, S.-H. Wu, Y. Hung, Y.-H. Chou, C. Chang, M.-L. Lin, C.-P. Tsai, C.-Y. Mou Chemistry of 
Materials. 2006, 18, 5170-5172. 
[116] J.-K. Hsiao, C.-P. Tsai, T.-H. Chung, Y. Hung, M. Yao, H.-M. Liu, C.-Y. Mou, C.-S. Yang, Y.-C. Chen, 
D.-M. Huang Small. 2008, 4, 1445-1452. 
 
 
 
47 
 
 
Chapter 2: Lipid Bilayer Coated Mesoporous Silica  
I. Chemically Reducible Lipid Bilayer Functionalized Mesoporous 
Silica: Biocompatibility and Controlled Release. 
A modified version of this section has been submitted for publication in Molecular 
Pharmaceutics. 
INTRODUCTION 
The development of mesoporous silica nanoparticle (MSN) technology for controlled 
release of pharmaceutical molecules has become a major research direction in the last 
decade. Recent developments have demonstrated that the high surface area, tunable pore 
sizes, and ordered mesostructure of functionalized MSNs all contribute to this controlled 
release property.[1, 2]  In addition to pharmaceuticals, MSN have been shown to deliver many 
types of biologically-relevant molecules including DNA, RNA and small proteins into cells. 
The release of these molecules by stimuli responsive methods, including several different 
capping and uncapping schemes are currently under development. The types of capping 
materials involve the use of quantum dots, iron oxide nanoparticles, dendrimer and several 
“molecular machine” caps.[3-9] 
Combinatorial techniques have allowed researchers to greatly expand the existing 
library of potential drug molecules since the mid 1980’s.[10]  While there are millions of 
potential target molecules available, it is vital to note how few actually are approved for 
human use.  In many cases the overall toxicity of the target molecule; insolubility and 
instability in biological systems, and undesired interactions (side effects) of the 
pharmaceutical can lead to the termination of promising clinical trials. [11]  In order to meet 
many of these challenges, various strategies are under development in order to encapsulate 
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pharmaceuticals to ensure delivery to the affected tissue and avoidance of detrimental side-
effects. 
With the unique pore structure of MSNs, guest molecules can be loaded and protected 
with these stimuli-responsive controlled release systems.  In addition to the mechanisms of 
controlled release listed above, liposomes have recently been introduced as potential 
supramolecules to assist in utilizing MSN for drug delivery devices.[12-18]  Their use as 
potential carriers of bioactive molecules has rapidly become apparent and several liposome-
derived pharmaceuticals have been developed and are already in use.[19]  There are several 
advantages to using liposomes as drug carrier systems including biodegradability, the ability 
to carry both hydrophilic and hydrophobic payloads, improving protein stabilization, and cell 
targeting.[20-27] However, liposomes have several drawbacks including a lack of stability to 
the wide pH range found in biological systems, a lack of long-term storage ability, and the 
need to formulate specific concentrations of the structural components such as lipids and 
cholesterols in order to achieve the most stable system.[28, 29]  Liposomes also undergo 
oxidative and hydrolytic degradation resulting in the loss of structure and the unregulated 
release of cargo molecules.  Recently, the groups of Brinker and Bein have utilized surface 
charge properties to demonstrate that a lipid bilayer can be stabilized on the surface of  
mesoporous silica particles and used to carry drug molecules.[12, 13] New work by Brinker et 
al. also demonstrates the ability of silica particles encased in lipid bilayers to target specific 
cells.[30]  Work by Ho and coworkers demonstrates the ability of a covalently bound inner 
leaflet and hydrophobically attached outer leaflet can result in material that is capable of 
interfacing with cells.[14]  
Herein, we report the synthesis, characterization and biological activity of a lipid-
bilayer supported MSN (LB-MSN).  The biocompatibility of the phosphorylated head group 
is explored by using pure coatings of one of four phosphorylated dipalmitoylglycerols 
including phosphatidylcholine (PC), phosphatidylethanolamine (PE), phosphatidic acid 
sodium salt (PA) and cardiolipin (CL) (Figure 1). 
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Figure 1. Phosphorlyated lipids comprising the cell-interaction layer of the LB-MSNs studied.   
These lipids differ in structure, charge, and cellular location and function and provide 
valuable insight into the importance of the formulation of the cell interaction layer (CIL) of 
the carrier particle.  An illustration describing the assembly of LB-MSN can be seen in 
Scheme 1.  
 
Scheme 1. Synthesis of lipid bilayer functionalized mesoporous silica nanoparticles (LB-MSN) showing layer-
by-layer assembly of the material. 
We also demonstrated the ability of our system to release a model compound (fluorescein) 
upon cleavage of the hydrophobic dipalmitoyl monolayer (DP) with the disulfide reducing 
agent, dithiothreitol (DTT).  Using confocal fluorescence microscopy, we tracked the 
internalization of fluorescently labeled LB-MSN.  Finally, we examined the relative cell 
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populations in several control experiments to show that phosphorylated lipids and MSN have 
a unique, synergistic effect in cellular interaction.   
 
Experimental 
 
Dipalmitoylphosphatidyl choline and dipalmitoylphosphatidyl ethanolamine were 
used as received from Avanti Polar Lipids Inc.  Dipalmitoylphosphatidic acid, cardiolipin, 
palmitic acid, dimethylaminopyridine, dicyclohexylcarbodiimide (DCC), 3-
mercaptopropyltrimethoxysilane (MPTMS) and 1-thiol-2,3-propanediol (TPD) were used as 
received from Sigma-Aldrich.  2,2’-dipyridyl disulfide was used as received from TCI 
America. Hoechst 33342 nucleus stain was purchased from Molecular Probes. Powder X-ray 
diffraction patterns were obtained on a Rigaku Ultima IV X-ray diffractometer using Bragg-
Brentano geometry using Cu K-α radiation and a 2.2 kW X-ray beam.  Nitrogen sorption 
isotherms were measured using a Micromeritics Tristar 3000 sorption analyzer.  Isotherms 
are interpreted using the Brunauer, Emmett and Teller (BET) method to calculate surface 
area and the Barrett, Joyner, and Halenda (BJH) method to determine pore diameters and 
volumes.  TEM micrographs were obtained on a Philips CM-30 using 110 kV accelerating 
voltage and ζ-potential of LB-MSN were obtained on a Malvern Zetasizer.   
Synthesis of 1-thiol-2,3-dipalmitoylpropane (TDPP): In 100 mL of dry 
dichloromethane, 1.08 g (10 mmol) of TPD, 2.27 g (11 mmol) of DCC and 2.82 g (11 mmol) 
of palmitic acid were added sequentially.  Dimethylaminopyridine (5-10 mg) was then added 
as a catalyst and the reaction was allowed to stir overnight at room-temperature.  The 
reaction mixture was filtered twice to remove precipitated dicyclohexylurea and extracted 
with 2 x 100 mL of 0.01 M HCl and one 100 mL of distilled water.  The organic layer was 
dried over anhydrous Na2SO4, filtered and the solvent was removed under reduced pressure.  
The residue was dissolved in ethanol and the product, 1-thiol-2,3-dipalmitoylpropane (TDPP) 
was recovered by recrystallization from ethanol.  TDPP is recovered in 83 % yield and 
spectral data match those found in the literature.[31]
Synthesis of dipalmitoyl functionalized MSN (DP-MSN): MSN was synthesized 
using our previously reported procedure and dried in vacuo for 6 h at 110 
  
oC.[32]  The MSN 
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surface was functionalized by grafting MPTMS at a concentration of 100 mM in refluxing, 
anhydrous toluene under an argon atmosphere.  The functionalized particles are removed via 
filtration and dried overnight (MP-MSN).  MP-MSN (1.0 g) is placed in 50 mL of dry 
methanol and 2.20 g of 2,2’-dipyridyl disulfide is added and the mixture is stirred overnight 
at room-temperature.  The resulting yellow mixture was filtered and washed with excess 
methanol and freeze-dried for several hours to yield pyridyl-disulfide MSN.  The pyridyl-
disulfide MSN was resuspended in 50 mL of dry methanol and 0.540 g (5.0 mmol) of TDPP 
was added and stirred overnight at room temperature.  Particles were filtered from the yellow 
mixture and washed with excess methanol to yield DP-MSN and freeze dried overnight.  
Synthesis of lipid bilayer MSN (LB-MSN): In a typical synthesis, approximately 10 
mg of DP-MSN is placed in a small vial with 10 mL of chloroform and sonicated for 10 
minutes to ensure good dispersion.  To this suspension 3 - 4 mg of the desired 
phosphorylated lipid was added.  The solvent was removed under reduced pressure to 
associate the phosphorylated lipid with the hydrophobic surface of DP-MSN, the material 
was freeze dried for approximately 3 hours.  The dried material was resuspended in pH 7.4 
phosphate buffer (ionic strength 10 mM) without NaCl and shook intermittently over the next 
30 minutes.  This step was repeated two additional times to remove excess phospholipid.  
The resulting LB-MSN was immediately used in further experiments or freeze-dried and 
stored at -20 o
Fluorescein loaded LB-MSN: In order to prepare fluorescein loaded LB-MSN, a 
methanol solution containing 250 mM of fluorescein and 2,2’-dipyridyl disulfide is added to 
250 mg of MP-MSN and stirred overnight.  After filtering, the powder was collected and 
placed in a methanol solution containing 250 mM of fluorescein and 0.90 g of the capping 
agent, TDPP, and stirred overnight at room temperature.  The solution was filtered and the 
powder lyophilized overnight.  
C to prevent degradation of the phosphorylated head groups of the CIL.  
The cell lines used in this study are immortalized HeLa (CCL-2) and normal mouse 
liver cells (CRL-6447) received from ATCC. Both cell lines were maintained in T-75 culture 
flasks using Dulbecco’s Modified Eagle Medium (DMEM) with 100 U mL-1 penicillin, 100 
μg mL-1 streptomycin, 2 μM L-alanyl glutamine and 100 μg mL-1 gentamicin. Media used in 
HeLa culture was further modified with 10% (v/v) donor equine serum while media used for 
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NLC was modified with 10% (v/v) fetal bovine serum. Cells were grown in an 
environmentally controlled incubator with a 5.5 % CO2 atmosphere and a temperature of    
37 °C and were subcultured every 3-4 days. All cytotoxicity measurements were obtained 
using a Millipore Guava flow cytometer. Cell toxicity measurements were carried out by first 
seeding six-well plates with 1x105 cells mL-1 of media and allowing 24 hrs for the cells to 
attach to the plate surface. Cells were then exposed to varying concentrations of MSN 
particles between 200 μg mL-1 and 25 μg mL-1 for 36 hours. Particle toxicity was recorded as 
the change in viable cell population from a control population that was not exposed to MSN 
particles. Confocal fluorescence micrographs were obtained using a Leica SP5 II confocal 
microscope. Cells were introduced to Wilco Glass Bottom dishes (GWSt-3512) at a 
concentration of 5x104 cells mL-1 and allowed to attach to the surface of the plate for 
approximately 24 hours. The cells were then exposed to media containing Hoechst 33342 dye 
for 30 minutes and then washed with fresh media. After washing, a 100 μg mL-1
 
 suspension 
of FITC labeled LB-MSN particles in modified DMEM media are then added to the cells and 
then immediately observed using confocal microscopy.      
Results and Discussion 
The material structure characteristics of MSN and DP-MSN were first examined by 
XRD, TEM, nitrogen sorption, TGA, and zeta potential. In Figure 2A, XRD patterns 
indicate that the hexagonal pore structure of the particle was well maintained through all 
synthetic steps.  Reduced intensity of the d100, d110, and d200 XRD peaks in the surface 
functionalized MSN are due to the pore-filling effects leading to a decrease in contrast 
between the pores and the framework as previously reported.[4]  In order to determine 
whether the pores are chemically accessible and to obtain the surface area, pore volume, and 
pore size of the MSN, the adsorption and desorption of nitrogen were measured (Figure 2B).  
Analysis of the nitrogen adsorption/desorption isotherms indicate that the material has a 
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Figure 2. A.) X-ray diffraction pattern of MSN, SH-MSN and DP-MSN. The intensities of the scans have been 
offset for clarity. B.) Nitrogen adsorption and desorption isotherms of MSN and DP-MSN showing that after the 
addition of the DP layer the pores of MSN are blocked.  Surface areas of MSN and DP-MSN are 1050 m2 g-1 
and 49 m2 g-1
typical type IV isotherm with a surface area of 1029 m2 g-1  and a pore volume of 0.85 cm3 g-
1 by the BET method.  A narrow pore diameter distribution (2.4 nm) was calculated by 
applying the BJH calculation to the adsorption isotherm and confirmed by TEM analysis.  
After capping the MSN with DP, the surface area significantly decreased to 49 m2 g-1. 
Utilizing the t-plot method developed by de Boer the external surface area of MSN was 
estimated to be approximately 50 m2 g-1.[33] The results of these analyses, along with the 
XRD results, indicate that the pores were completely blocked by DP, encapsulating guest 
molecules before the CIL was added to the DP-MSN.  Parallel channels were observed in the 
TEM images of the MSN, DP-MSN, and LB-MSN indicating the MCM-41 type pore 
structure was not destroyed by attachment the organic lipids to the surface.  Transmission 
electron microscopy investigations of the MSN with both the DP and CIL moieties also 
provided direct visual evidence of the total coverage of the MSN (Figure 3).  Due to contrast 
restraints with the surface bound organic layer and the MSN in the TEM, we were unable to 
visualize the DP and LB layers on the MSN.  In order to observe the presence of the DP and 
LB layer, samples of MSN, DP-MSN, and LB-MSN were each exposed to a 2% (w/w) 
solution of uranyl acetate.  Uranyl acetate binds to the oxygen containing phosphate groups 
of the lipids in the CIL of the LB-MSN.  The LB-MSN (Figure 3f) stained in this manner 
show greater contrast with a dark ring around the particle while DP-MSN, which lacks 
phosphate groups (Figure 3e) appear identical to the unstained control micrograph (Figure 
3a).   
, respectively. 
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Figure 3. TEM micrographs showing MSN unstained and stained with uranyl acetate (A. and D.), unstained 
and stained DP-MSN (B. and E.) and unstained and stained LB-MSN (C. and F.). Arrows have been added 
clarify locations of high contrast due to uranium staining. 
Unstained samples of LB-MSN show that the pore structure of the LB-MSN was maintained 
(Figure 3c). 
In order to test the ability of DP molecules to be cleaved from the surface of MSN 
and release the fluorescein from the pores in a controlled manner, fluorescein loaded LB-
MSN was exposed to various concentrations (0.5 mM, 1 mM and 2 mM ) of the disulfide-
reducing molecule, dithiothreitol [34]. The release of fluorescein from the pores of LB-MSN 
was dependent on the concentration of the disulfide reducing trigger (Figure 4).[34]  The 
fluorescein loaded LB-MSN exhibited approximately 15%  
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Figure 4. Controlled release of fluorescein from LB-MSN using dithiothreitol disulfide reducing agent is 
introduced at 240 min (black arrow). Control sample is LB-MSN with loaded fluorescein but no disulfide 
reducing molecule is added, DP-layer control is described in the supporting information. 
release of fluorescein in 10 mM PBS in 10 h prior to the addition of the DTT.  This result 
suggests that the lipid bilayer is an efficent, but somewhat permeable cap for encapsulating 
fluorescein.  The addition of DTT to the aqueous suspension of LB-MSN triggered a rapid 
release of the encapsulated fluorescein.  Within 1.5 hr, nearly 100% of the total release was 
reached in the experiment with the greatest DTT concentration (2 mM). In previous studies 
demonstrating controlled release of guest molecules from the pores through cleavage of 
disulfide linked caps, release was generally completed within 24-72 h post addition of the 
disulfide reducing agent.[4, 35]  Release of fluorescein from LB-MSNs using glutathione as the 
disulfide reducing agent is described in the supporting information. A calibration curve was 
established for fluorescein and it was calculated that LB-MSNs are capable of releasing 
approximately 14 μmol fluoroscein g-1 LB-MSN into a 10 mM, pH 7.4 PBS solution.  
Incubation of LB-MSN with both HeLa and normal liver cells (NLC) was performed 
to examine the biocompatibility and cytotoxicity of the MSN-lipid system.  The flow 
cytometry results, in Figure 5, 
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Figure 5. Cytotoxicity of varying concentrations of MSNs in HeLa cells. While the DPPC control sample 
shows increased cell populations at all concentrations, comparisons of LB-MSN (DPPC) and the DPPC control 
and of MSN and MSN + DPPC indicate that DPPC is more effectively delivered to the cell when chemically 
supported by MSN. Growth data is normalized against the growth of the negative control, cells not exposed to 
LB-MSN. 
demonstrate increased biocompatibility of LB-MSNs with a CIL of dipalmitoylated PC over 
controls containing MSN and MSN physically mixed with DPPC.  In fact, the cells incubated 
in the presence of LB-MSN (DPPC) showed greater cell populations at some concentrations 
than the negative control that did not have any MSNs present.  Specifically, it was observed 
that LB-MSNs functionalized with PC actually enhanced the growth of both HeLa and NLC 
at LB-MSN concentrations below 200 μg mL-1.  Research into possible biochemical 
pathways leads to the hypothesis that the observation of enhanced growth is due to the 
increased availability of diacylglycerol phosphatidylcholine (DAG-PC). While this indicates 
that higher concentrations of LB-MSNs would provide increased cell proliferation over lower 
concentrations, it is hypothesized that the toxicity of these particles at high concentrations 
mediate this effect.[36-38] The hydrolysis of DAG-PC by phospholipase D (PLD) results in 
diacylglycerols (DAGs) and phosphatidylcholine (PC).[39] Phospholipase D has been found to 
be active in most cells during endocytosis and can be found at increased concentrations in 
many cancer cell types.  Additionally, PLD has also been shown to cooperate with several 
tyrosine kinases in order to increase cell survival and proliferation.[40]  Diacylglycerols have 
been shown to be potent upregulators of protein kinase C activity resulting in stimulation of 
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the ras/raf/MEK/MAPK mitogenic pathway [41]. It has been determined that when cells 
accumulate a critical concentration of phosphatidylcholine, the transcription factor Sp1 binds 
to the proximal promoter of cytidylyltransferase- α resulting in DNA transcription during the 
S-phase of mitosis.[42] However, without sufficient co-factors for enzyme pathway activation 
it was determined that PLD is saturated with DPPC at low concentrations and that enzymatic 
turnover to DAG and PC is very low even when 98% of the enzyme is bound to DPPC 
substrate.[43] This indicates that even though a high local concentration of DPPC may be 
achieved in cells, very little additional DAG and PC are generated at these high 
concentrations, resulting in little increase to mitogenic signaling. If only a small amount of 
mitogenic up-regulation is achieved through DPPC activation, then proliferation is not 
expected to completely negate the intrinsic cytotoxic effects of the material. 
In order for a particle to be considered as a drug delivery system, the particle must be 
able to enter cells.  To determine if LB-MSN are able to enter cells, we covalently labelled 
LB-MSN with fluorescein isothiocyanate (LB-MSN-F) and examined the cells of interest 
using confocal fluorescence microscopy.  In order to assess whether the LB-MSN were 
internalized, we examined both HeLa and NLCs shortly after adding a suspension of LB-
MSN-F to the cells growing on the glass slide.  We utilized a nucleus staining dye to be 
certain that the focal plane being observed intersected a cell.  We also utilized an endosomal 
dye to attempt to identify the mode of internalization of LB-MSN-F.  Overlay of the confocal 
images at the same z-distance showed both the nucleus (blue) and the LB-MSN-F (green) 
indicating that the LB-MSN-F are inside of the cells due to the close proximity to the nucleus 
(Figure 6a & 6d).  The images overlaying the red and green channels identifying the 
location of the endosomes and LB-MSN-F must be considered inconclusive, this is due to the 
possibility that the lipophilic dye used to stain the endosomes eventually mixes with the LB-
MSN which could potentially result in dual labeling of the particle (Figure 6c & 6f). 
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Figure 6. Confocal fluorescence microscopy images of HeLa (A, B, C) and NLC (D, E, F) showing internalized 
LB-MSN particles (green), endosomes (red) and cell nuclei (blue). Images A and D show only green fluorescent 
particles, images B and E show only red endosomes and images C and F show overlays of the two channels. 
     
Thermogravimetric analysis (TGA) data obtained from PC-MSN was used to 
determine the total amount of PC present on a sample of LB-MSN (supporting 
information).26  TGA analysis of DP-MSN shows that approximately 20% of the mass of the 
particle is composed of 1-thiol-2,3-dipalmitoyl propane (TDP). LB-MSNs examined by TGA 
showed a 40% by mass of TDP and CIL combined, resulting in approximately 20% of the 
total mass of the LB-MSN coming from the CIL. This data was then used to design a control 
experiment in which HeLa and NLCs were exposed to concentrations of free DPPC 
equivalent to concentrations bound to the surface of LB-MSN.  This experiment shows that 
free DPPC at similar concentrations found on the external surface of the LB-MSN has 
negligible effect on the growth rate of HeLa or NLC lines.[44]   Biocompatibility data of MSN 
and DP-MSN were obtained in order to determine the effectiveness of the CIL in remediating 
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particle toxicity.30  In contrast, a direct comparison of the cytotoxicity of all LB-MSN 
materials at 100 μg mL-1 demonstrates optimal biocompatibility upon the incorporation of a 
complete lipid bilayer system composed of a terminal choline group on the surface of MSN 
(Figure 7), in fact this sample showed a 20% increased 
 
Figure 7. Cytotoxicity measurements of LB-MSNs with different phosphorylated lipids in the CIL in HeLa (A.) 
and Normal Liver Cells (NLC, B.). All cell populations are for a 36 hour exposure of 100 μg(LB-MSN) mL-1
cell proliferation over the negative control.  Finally, in order to determine whether the nature 
of the polar headgroup of the phospholipids attached to the MSN affected cellular function, 
phosphatidylethanolamine (PE), phosphatidic acid (PA), and cardiolipin (CL) were all 
investigated for cytotoxicity in HeLa and NLC (supporting information).  We expected the 
following trend in biocompatibility based on biological aspects of the various phospholipids 
PC > PA > PE > CL including the ζ-potential of LB-MSN suspensions (Table 1).   While 
phospholipids with the PA and PE headgroups are also found in cell membranes, the total 
amount present on these cells is only several percent and were not expected to influence cell 
proliferation.  It has been reported that PA and PE containing phospholipids with two 
palmitoyl chains are not as effective at up-regulating mitosis pathways as phospholipids 
containing the natural C16-C18 saturated and C18-C20 unsaturated lipid chains.[45] 
 of 
cell culture medium. Experiments detailing the cytotoxicity of LB-MSNs across a range of concentrations for 
each CIL head-group are available in the supporting information.  Growth data is normalized against the growth 
of the negative control, cells in normal growth media. 
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Phospholipid 
ζ-potential 
(mV) 
Error 
(mV) 
PC -12.6 ± 2.3 
PA -26.7 ± 0.8 
PE -28.6 ± 1.8 
CL -65.8 ± 2.9 
 
Table 1. Zeta -Potentials of LB-MSNs bearing different phosphorylated headgroups in the cell interaction layer 
(CIL). 
In contrast to data from the PC headgroup toxicity studies, materials containing CL-
lipids cause a decrease in the cell population.  This is thought to be due to the fact that CL 
containing lipids are most often found on the inner leaflet of mitochondria.  When the cell 
begins to undergo apoptosis, CL binds to cytochrome C resulting in a non-native 
conformation which provides a direct channel for H2O2 to access the heme region of the 
protein.[46]  Binding of cytochrome C in this manner has been shown to be an essential step in 
continuing the apoptosis cascade in many cell types.[47]   
Conclusion 
To summarize, we have successfully synthesized a mesoporous silica nanoparticle 
supported lipid bilayer system with a high degree of dispersability and the ability for rapid 
and diverse CIL functionalization.  Cytotoxicity experiments show that our system is 
biocompatible and the degree of compatibility can be altered by changing the composition of 
the CIL.  Additionally, we have shown that it is possible to release a model molecule, 
fluorescein, from the pores of LB-MSN via a chemically triggered disulfide reduction.  
Finally, we proved, utilizing confocal fluorescence microscopy, that LB-MSNs containing 
PC in the CIL enter HeLa and NLCs very rapidly.  All of these data indicate that lipid bilayer 
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coated-MSNs could potentially be used to design a drug delivery system capable of 
controlled release. 
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II.  Haemocompatibility of lipid bilayer functionalized large-pore 
mesoporous silica 
During the proceeding decade, research into materials for use as pharmaceutical 
delivery devices has seen considerable growth. However, questions regarding toxicity and 
circulation of these systems have not been fully answered, and for many nanomaterials the 
information available is inadequate. One of the major issues surrounding the safety and 
efficacy of such delivery platforms is that of haemocompatibility. A material capable of 
releasing a pharmaceutical compound on demand is neither safe nor effective if damage is 
produced among circulating red blood cells (RBCs). The deleterious effects of a RBC-
incompatible system could potentially range from bruising at the inoculation site, 
immunogenic response, and embolism which can lead to infarction and stroke. In order to 
minimize these risks, covalently-linked lipid-bilayer functionalized large-pore mesoporous 
silica has been developed. These hybrid materials are shown to be capable of interfacing with 
RBCs without damaging the cells even at relatively high concentrations. Additionally, a 
small change in outer bilayer composition is shown to produce toxic effects without resulting 
in haemolysis.    
Introduction 
The necessity to minimize cytotoxic effects of promising pharmaceutical molecules 
and increase the efficacy of existing pharmaceuticals has lead to the development of many 
types of drug delivery devices. Among these, silica based particles have been extensively 
researched in regards to their ability for releasing a cargo upon exposure to the correct 
stimulus, which can include such triggers as pH, light, disulfide reducing agents, enzymes 
and magnetic fields.[48-56] While drug release and even cell-specific targeting have been 
demonstrated, there is still a need to fully understand how nanoparticle systems will affect 
other areas of the body besides the intended target.[57-59] The majority of recent work has 
been to decrease fouling caused by non-specific protein binding and to increase the 
haemocompatibility of device surfaces by using by using pendant PEG groups.[60-62] 
However, particles and surfaces that have been prepared to mimic the surface charge or 
protein composition of the red blood cell or the use of erythrocyte ghosts to reduce toxicity 
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and increase circulation times have been studied for several decades. A powerful strategy for 
obtaining biocompatible particles is to enclose the particle in within a lipid bilayer structure. 
Lipid bilayer coated particles have been shown to be effective immunoadjuvants, drug 
delivery devices, and as a platform for biologically active saccharide to bind with cholera 
toxin.[63, 64]   Additionally, this method has proven effective in modeling RBCs for studying 
protein insertion and structure via NMR and for studying phagocytosis of healthy and sickle 
RBCs.[65, 66] Future advancements in silica-particle-based therapeutics will require definitive 
knowledge of in-vivo effects, especially haemocompatibility.  
With the goal of synthesizing a nanodevice capable of safely interfacing with human 
RBCs, we investigated the properties of lipid bilayer-coated large-pore mesoporous silica 
nanoparticles (LB-l-MSN). Currently, haemotoxicity reports on silica nanoparticle systems 
(SNPs) are limited to morphological effects of the particles on haemocompatibility and 
biodistribution.[67-69] To the best of our knowledge, using mixtures of phosphorylated lipids 
and cholesterol to mimic the surface of red blood cells on mesoporous silica particles has not 
been published. Previous reports have shown that MSNs possessing small pores and small, 
regular particle sizes (e.g. 100 – 200 nm) are haemocompatible to concentrations of 100 
μg/mL. [68]   In contrast, solutions of l-MSNs (≈ 800 nm) do cause significant haemolysis 
detected by UV-vis analysis and the naked eye, an observation also seen by Hudson et al. in 
regards to a similar SBA-15 mesoporous silicate.[70]  This incompatibility with RBCs has 
been theorized to be due to interactions between the negatively charged l-MSN particle and 
positively charged phosphatidylcholine lipids in the outer RBC membrane. As the size of the 
particle increases, less energy is required to deform the RBC membrane allowing for more 
contact between RBC and particle. Examinations of flow cytometry data in this study 
indicate a high degree of association between particles and RBC; however TEM evidence 
indicates that LB-l-MSNs are not internalized by the RBC, which is in contrast to the 
observed behaviour of l-MSNs in our previous study.            
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Experimental Section 
Large pore MSNs (l-MSN) were synthesized via our previously reported 
procedure.[71] The surfactant Pluronic P-104 (7.0 g) as was added to a solution of water (164 
g) and 4 M HCl (109 g) and stirred at exactly 55 oC for one hour in a sealed Erlenmeyer 
flask. Tetramethylorthosilicate (TMOS, 10.64 g) was then added at once and the mixture is 
stirred for an additional 24 hours at 55 oC. The mixture is then added to a Teflon lined 
autoclave and treated at 105 oC for 24 hours. The product was then isolated via filtration, 
washed sequentially with water and methanol and then lyophilized overnight before further 
modification. Surfactant is removed via calcination; the l-MSN is placed inside a furnace and 
slowly ramped (1.5o/min) to 550 oC and allowed to stand at that temperature for 4 hours. The 
material is then characterized via powder X-ray diffraction and nitrogen sorption analysis 
(BET and BJH methods). Particles labeled with fluorescein are prepared by mixing 2 mg of 
fluorescein isothiocyanate with 7 μL of 3-aminopropyltrimethoxysilane in 2 mL of 
anhydrous acetonitrile or DMSO and allowed to react for 10 minutes. The mixture is then 
directly added to 1.0 g of l-MSN stirring in 50 mL of anhydrous toluene at 115 oC and 
allowed to react overnight. The product is then collected via filtration, washed with methanol 
and lyophilized overnight resulting in fluorescein labeled l-MSNs (l-[f]MSN). 
The lipid-bilayer functionalized particles are synthesized according to our previously 
reported method. Particles with surfactant removed (1.0 g) are dried in vacuo overnight at 
110 – 115 oC, the flask is then back-filled with argon. A solution of anhydrous toluene (50 
mL) and 100 mM mercaptopropyltrimethoxysilane (MPTMS) is then quickly added to the 
flask and stirred at 115 oC for 24 hours. The product is then filtered and washed with copious 
amounts of methanol to remove any unreacted MPTMS and is then dried in vacuo for 
approximately 8 hours. The product (1.0 g) is then resuspended in 50 mL of alumina-dried 
methanol and 2,2’-dipyridyl disulfide is added and the mixture stirred overnight. The product 
is again filtered and washed with copious amounts of methanol and then immediately 
resuspended in 50 mL of alumina-dried methanol and 1-thiol-2,3-dipalmitoylpropane (0.540 
g) is then added to the flask and allowed to stir for an additional 24 hours. The product is 
filtered, washed with methanol, and lyophilized overnight resulting in a highly hydrophobic 
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dipalmitoyl functionalized l-MSN (DPl-MSN). This hydrophobic l-MSN is then placed into a 
solution of containing 1 mg/mL of the desired bilayer constituents in chloroform. In this 
study we have examine the effects of a simple dipalmitoyl phosphatidylcholine bilayer and 
one that more closely mimics the surface of the red blood cell, possessing a composition of 
40% dipalmitoylphosphatidly choline, 10 % dipalmitoylphosphatidyl ethanolamine, and 50% 
cholesterol by weight (mRBC).[72, 73] During a typical synthesis, 10 mg of DPl-MSN is 
placed into a 20 mL glass scintillation vial and cholorform/outer layer solution added so that 
there is a total of 3 mg of membrane constituent, cholorform is then added to a total of 10 
mL. The mixture is then sonicated for several seconds and allowed to stand approximately 30 
minutes with intermittent shaking. The chloroform is then removed via rotary evaporation 
and 10 mL pH 7.4 phosphate buffer (no NaCl, 15 mM Pi) is added. The mixture is sonicated 
again for several seconds to detach the particles from the wall of the vial and then allowed to 
stand another 30 minutes with intermittent shaking. Mixtures are then transferred to glass 
centrifuge tubes and particles are sedimented at 1500 RPM for 10 minutes. The phosphate 
buffer is decanted, an additional 10 mL of buffer is added, the particles are then resuspended 
with mechanical shaking and centrifuged a second time. After the second decantation of the 
buffer, the particles are ready to be used in further experiments.           
Approximately 4 mL of human blood sample (ethylenediamine tetraacetic acid 
stabilized) was freshly collected from the Occupational Medicine office, Ames Laboratory 
and was centrifuged at 1600 rpm for 5 minutes. The plasma and buffy coat layers were 
removed and the remaining RBCs were washed with sterile isotonic PBS. After washing the 
RBCs five times with PBS, no traces of plasma were seen in the supernatent solution.  The 
packed RBCs were used for all the experiments. 
For labeling with PKH26 (red fluorescent cell linker kit, Sigma, USA), 100μL of 
packed RBCs were suspended in 1 mL of diluent C and then mixed with 1 mL of diluent C 
containing 4 μM PKH26 followed by incubation at room temperature in the dark for 5min. 
The reaction was stopped by adding 1 mL of plasma (heat inactivated at 57 ˚C in oil bath for 
1h beforehand). The stained RBCs were then centrifuged at 1600 rpm for 5 min followed by 
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six washing cycles with PBS to remove the excess and free pKH26 dye. The labeled RBCs 
were used for flow cytometry analysis and confocal fluorescence microscopy. 
For haemolysis experiment, 200 μL of packed RBCs were diluted to 4 mL with PBS 
(5% hematocrit) and the diluted RBC suspension (0.2 mL) was mixed with 0.8 mL of  l-MSN 
suspensions in PBS at 25, 50, 100 µg/mL concentrations. Water and PBS (0.8mL) incubated 
with 0.2 mL diluted RBC suspension served as positive and negative control, respectively. 
All the mixtures were gently vortexed and incubated at room temperature for 2 h. The 
mixtures were then centrifuged at 1600 rpm for 5 min. The supernatant was transferred to a 
cuvet and the absorbance was measured at 541 nm by Agilent UV-visible spectrometer. The 
following formula was used to calculate the percent haemolysis of RBCs. A table of the 
haemolysis results is available in the SI. 
 
200 µL of PKH26 labeled RBCs at 5x106 cells per mL were mixed with 200 μL of 
FITC-l-MSN suspensions in PBS at 20 μg/ mL to make the final nanoparticle concentration 
10 µg/mL and incubated at room temperature for 2h. An aliquot of sample (10 µL) was 
mounted in between two plastic coverslips and imaged using 
  The diluted RBC suspension (0.2 mL) was mixed with 0.8 mL of l-MSN suspensions 
in PBS at 25, 50, 100 µg/mL concentrations and incubated at room temperature for 2 h. The 
samples were then fixed by adding a 1% glutaraldehyde solution in PBS dropwise over 5 min 
and further incubated at 37 ˚C for 1.5 h, followed by postfixation with 2% osmium tetroxide 
in PBS for 1.5 h. The RBCs were then dehydrated in increasing concentrations of ethanol 
(50, 60, 70, 80, 90, 95 and 100%) for 15 min each. 10µL of cell suspensions were dropped 
onto plastic coverslips, dried, and coated with iridium before viewing under a FEI Quanta 
250 FEG scanning electron microscope. 
The same procedure for preparing samples for SEM imaging was also used for 
preparing, fixing and dehydrating the samples followed by staining with 1% uranyl acetate in 
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70% ethanol at room temperature overnight. The cells were washed three times with pure 
acetone and embedded in Epon. The embedded samples were sectioned in 80 nm thick slices 
on a Leica Ultracut sliding ultramicrotome. Thin sections were supported on copper grids 
with carbon film and examined in a Tecnai G2 F20 microscope operated at 200 kV. 
Results and Discussion 
In this study, two lipid bilayer compositions (mRBC and DPPC) were tested for 
haemocompatibility and compared with our previously published data. Physical 
measurements were obtained including TEM, SEM, XRD and nitrogen sorption isotherms 
confirming an expected spherical morphology and 2D-hexagonal pore structure (See 
Supporting Information). Zeta-potential measurements of l-MSNs, DPPC-l-MSNs and 
mRBC-l-MSNs are summarized in Table 1. At physiological pH, silanol groups (pKa ≈ 4) on 
the particle surface are deprotonated, imparting a negative charge to the particle.    The 
haemolytic activity of LB-l-MSNs on RBCs was observed using UV-Vis measurements  
 
Figure 1. UV-Vis spectra of test for haemolytic activity of LB-l-MSNs. Spectra have been plotted on a Log y-
axis for better visualization of traces. Uncoated l-MSNs show high haemolytic activity, roughly 40% of the 
positive haemolysis control of RBCs in water. In contrast, both LB-l-MSNs in A. (DPPC) and B. (mRBC) show 
haemolytic activity near or below that of the negative haemolysis control, RBCs in PBS buffer. The baselines of 
l-MSNs are shifted due to scattering of yellow-red wavelengths by particles. 
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Figure Y. Photographs of the results of haemolysis assays in figure X. Labels I, II, III, and IV correspond to red 
blood cells under the following conditions; PBS, water, PBS with DPPC l-MSN, and PBS with mRBC l-MSN 
respectively. The panels A, B and C correspond to experiments with differing concentrations of MSN (25 
μg/mL, 50 μg/mL, and 100 μg/mL of particles respectively). Only the positive haemolysis control sample 
showed any significant visible haemolysis.  
(Fig. 1) and regular photography (Fig. 2). Surprisingly, l-MSNs functionalized with lipid 
bilayer architecture do not cause any measurable haemolysis above that of the negative 
control. Visual inspection of the haemolysis experiments shows a clear color differential 
between samples with small and large amounts of haemolysis. Studies on other particle 
systems has determined that increasing positive charge of the particle leads to decrease in 
haemolysis.[74]  This may be due to the attraction between the negative surface charges of the 
particle and the positively charged choline-lipids that make up the majority of the RBC outer 
membrane. The ion interaction provides enough energy to cause a deformation of the RBC 
membrane which may result in spiculation or haemolysis of RBCs.[68] Additional studies 
have also shown that RBCs in an acidic environment are more prone to crenation which can 
then lead to the generation of spicules.[75, 76] Acidic silanol groups on the surface of MSN 
may potentially create acidic microenvironments upon association with the RBC membrane 
promoting membrane deformation and eventually spiculation. While LB-l-MSNs have been 
shown to cause virtually no haemolysis, this may have been to low association of particles 
with RBCs. In order to determine the amount of particles associated with RBCs, flow 
cytometry measurements of fluorescein labeled LB-l-MSNs mixed with PKH26 labeled 
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RBCs were performed. A series of controls was carefully selected to ensure that signals from 
RBCs associated with LB-l-MSNs do not overlap with signals from unassociated cells. The 
results of these experiments indicate that all of the particles in solution are closely associated 
with RBCs (Figure 2). Interestingly, while LB-l-MSNs are observed to produce a unique 
signal (l-MSN (-) samples), this signal was not observed when particles were mixed with 
RBCs, indicating that all LB-l-MSNs are associated with RBCs. Since it is possible that the 
dye labeling RBCs could become adsorbed by LB-l-MSNs, controls (l-MSN(+)) were 
established in which MSNs were exposed to PKH26. Measurements from flow cytometry 
show no signals in the gated region for PKH26 and LB-l-MSNs can be observed in the 
normal region for fluorescein labeled particles (Supplemental Info).  Further evidence 
demonstrating the haemocompatibility of LB-l-MSNs, specifically mRBC l-MSN, was 
observed during SEM measurements of fixed RBCs (Figure 4). The series of      
 
 
 
Figure 3. The results of flow cytometry measurements. RBC (-) and (+) controls confirm positive labelling by 
PKH26 marker. Samples mRBC and DPPC l-MSNs were evaluated based on the number of RBCs that were 
observed to also be positive for fluorescein fluorescent signals. mRBC and DPPC l-MSN (-) and (+) controls 
show that fluorescein-labelled particles do not exhibit and fluorescent signals in the region expected for PKH26.  
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Figure 4. SEM micrographs of RBCs. Cells in panels A and D are control populations not exposed to MSNs. 
RBCs in panels E and F are exposed to concentrations of DPPC l-MSNs at 50 μg/mL, cells associated with 
particles show a large amount of damage in the form of spicules. Panels C and F show RBCs exposed to 
concentrations of mRBC l-MSNs at 50 μg/mL. RBCs in these images appear largely undamaged even when 
clearly associated with particles. 
micrographs illustrates how changes in the composition of the outer bilayer of MSNs can 
affect the RBC morphology. In our previous study by Zhao et al.,l-MSNs have been shown to 
be associated with spiculated RBCs under SEM observation. The control population of RBCs 
(Fig. 4A and D) shows only normal discocytes, while RBCs exposed to DPPC l-MSNs show 
a large proportion of spiculated cells of echinocyte phase II and III associated with the 
particles (red circles)(Fig. 4B and E).[77] A smaller proportion of RBCs which do not appear 
to be damaged can be observed with particles on their surfaces (green circles). When the 
composition of the particle lipid bilayer was changed to mRBC, the majority of cells 
observed appear as normal discocytes and spiculation of cells appeared to proceed no further 
then echinocyte I phase (Fig. 4C and F). \ 
While initial haemolysis and flow cytometry data showed good haemocompatibility 
of DPPC l-MSNs, the SEM micrographs prove that due to the large amount of damaged 
cells, DPPC coating would have adverse affects on the ability of RBCs to deform when 
passing through capillaries, leading to possible clots and necrosis. There is also evidence in 
recent toxicological studies that shows a sharp increase in silicon concentration of the spleen 
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and liver shortly after the administration of MSNs, especially when the dose is given 
intravenously.[36, 67] The close association of MSNs and RBCs observed with flow cytometry 
coupled with the sharp increase Si concentrations of the spleen indicate that RBCs are being 
spiculated and removed from circulation in the spleen by normal biological process.[78]  In 
contrast to DPPC l-MSNs, particles coated with mRBC do not appear to cause spiculation of 
RBCs by SEM analysis. This evidence coupled with the lack of haemolysis and close 
association of particles and RBCs indicates that mRBC coated particles may be better 
candidates as drug delivery devices due to a more biocompatible coating.  
 During the course of our previous study, TEM observations showed that l-MSNs 
were enveloped by the RBC membrane.[68] While there are several systems that utilize the 
interior of the red blood cell to deliver cargo, this was not the intended purpose of the LB-l-
MSN drug delivery system. Instead, by using mRBC coatings we hoped to avoid deformation 
of RBCs at all. Micrographs of LB-l-MSNs show markedly less local deformation than 
unfunctionalized l-MSNs(Figures 5 - 7). Similar to SEM observations, mRBC l- 
 
Figure 5. Large Pore MSNs coated with phospholipids which roughly approximate the RBC membrane. MSN’s 
are shown to be in contact with the red blood cell membrane, however deformation of the red blood cell 
membrane, spiculation of the cell and endocytosis of the particle is not observed.  
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Figure 6. Large pore MSNs coated with only dipalmitoylphosphatidylcholine (DPPC). MSN is shown to be in 
contact with a spiculated cell. Deformation of the red blood cell membrane is also observed at the corner of the 
particle (highlighted). Unlike uncoated LP-MSNs, endocytosis of the particles is not observed in TEM images.  
MSNs in contact with RBCs do not appear to cause spiculation and DPPC l-MSNs appear in 
contact with spiculated RBCs. In contrast to our previous study, neither mRBC nor DPPC 
coated l-MSN was observed to be engulfed by the RBC membrane.   
Conclusion       
Biomimicry is one of the most powerful tools that scientists have for exploring the 
human body and treating our various diseases and ailments. This is clearly shown by 
affecting a seemingly minor change in the lipid bilayer composition of l-MSNs. By altering 
the composition of the particle-supported outer bilayer to one which more closely matches 
the composition of a red blood cell, we were able to transform the LB-l-MSN system from 
one with a serious incompatibility (causing RBC spiculation) to a system that appears 
completely biocompatible. This study also outlines the importance of establishing guidelines 
for determining biocompatibility, as the haemolysis assay to determine deleterious effects of 
the particles on RBCs used by most researchers did not detect the change in RBC 
morphology that could lead to potentially harmful effects should similar mesoporous silica 
systems be tested in vivo or, in the long term, actual human test subjects. Adoption of 
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guidelines regarding nanoparticle toxicity evaluation, in addition to saving lives of current 
and future workers and researchers in these fields, may prove to save millions of dollars in 
the testing of systems that appear compatible except for a small difference that may not 
appear under the majority of currently applied tests.    
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Chapter 3: Synthesis of New Materials using the 
Hydrolysis and Condensation of Alkoxysilane 
Precursors 
 
Introduction 
The “bottom-up” synthesis of new materials represents a powerful driving force in 
science and technology research today. This synthetic method provides a fine degree of 
control for assembling highly ordered materials. Of particular interest are mesoporous silica 
particles (MSPs). Bottom up synthesis of MSPs allows for the control of particle 
morphology, size, surface area, pore size and pore volume. Additionally, the methods are 
generally tolerant to a large variety of functional groups, allowing for organic transformation 
of the MSP surfaces in order to achieve synthetic and scientific goals.  
 
The general method of MSP synthesis, utilized by researchers across the world, 
requires control of two main factors. The first is control over the templating agent. Altering 
concentrations of the organic templating agent will influence the MSP’s morphology, particle 
size, and pore size.[1-4] The second factor requiring fine control is reaction kinetics of the 
silica precursor or precursors. The rate of Si-O-Si bond formation also has the ability to 
influence the physical properties of the final product.[5] Modifying the organic functional 
groups, in addition to framework properties, enables MSPs to function in a wide variety of 
applications including (bio)chemical analysis, catalysis, therapeutic devices, energy 
storage/generation devices, and templates for other materials.[6]          
 
Our approach uses a two step mechanism for producing the Si-O-Si bond; hydrolysis 
and condensation of an alkoxysilane precursor (Scheme 1). The rates of these two reactions 
are mainly controlled by adjusting the pH of the solution or the alkoxy groups of the silicon 
precursor. Counterions in acids or bases used to adjust the pH have also been shown to have 
an effect on the physical characteristics of the particle.[7, 8] This range of effective working 
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pHs indicates that silicate materials are stable from pH 2 – 11 and indeed synthesis is 
performed across all of these pH ranges.   
 
Scheme 1. Stepwise hydrolysis and condensation of an alkoxy silane precursor. Single silane molecules may 
undergo multiple hydrolysis steps before beginning condensation or silica oligomers undergo further hydrolysis 
of unreacted alkoxy groups until all alkoxy groups have been converted to Si-O-Si or Si-OH bonds.     
 
I. Synthesis of a New Mesoporous Silica Nanoparticle from Water in 
Oil Emulsion  
Introduction 
The original impetus for this project was three-fold; first was the development of a 
truly spherical large-pore (pore diameter > 7 nm) mesoporous silica nanoparticle (MSN). The 
second was to develop reaction conditions that could be modified in order to accommodate 
the later synthesis of particles with different metal-oxide frameworks via condensation 
method. Lastly, we desired a fast, low-temperature method to generate a truly spherical 
particle. The current synthesis of large pore mesoporous silica particles takes 72 hours and 
relies on high temperatures to achieve large pore size, resulting in a particle that is actually a 
hexagonal prism. It was for these reasons that water-in-oil (W/O) emulsion was chosen as the 
synthetic medium. In terms of morphological control, W/O emulsion allows for control of the 
particle size through control of the water droplet “reactor” size. Stabilization for the water 
droplet is provided by an amphiphilic block copolymer. Since the silica precursors in the 
hydrolysis and condensation reaction are hydrophilic, formation of the MSN occurs totally 
within the water droplet.[9] Several examples of mesoporous silica materials formed in W/O 
emulsions have been previously published, however the majority of these studies employ 
non-ionic multi-bloc copolymers.[10-13]  
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Experimental 
The surfactant, cetyltrimethylammonium bromide (CTAB), silica precursor, 
tetraethylorthosilane (TEOS), decane, and citric acid were purchased from Sigma Aldrich 
and used as received. Arlacel P-135 (AP, Cithrol™), an ABA diblock copolymer (A = 
polyhydroxystearate, B = 30-polyethyleneglycol) employed as an emulsion stabilizer was 
generously donated by Croda International Plc. 
 
All materials in this study were prepared via the following synthetic method; first, a 
stock solution containing the appropriate weight% of CTAB was added to a flask. Secondly, 
the appropriate volume ratio of decane was added. The solution was allowed to stir rapidly to 
form the W/O emulsion, for solutions containing higher concentrations of CTAB and/or AP, 
mild heating was required to dissolve all constituents (flasks were then allowed to cool to 
room temp. before subsequent additions of reagents). This was followed by the addition of 
AP, citric acid and ammonium hydroxide and with stirring to homogenize reactants. Finally 
TEOS was added rapidly to the flask and stirred for 24 hours. Reaction mixtures were then 
centrifuged at 9000 g for 15 min. and the decane layer was decanted and saved for 
repurification. Methanol was then added to the remaining mixture and centrifuged again at 
9000 g for 15 min., the supernatant was decanted and washed twice more with methanol and 
once with acetone before being placed in a lyophilizer and dried overnight. A complete list of 
all experiments performed is available in appendix C.  
 
The materials were characterized via the following methods; the first, X-Ray 
diffraction (XRD), was performed on a Rigaku Ultima IV powder X-ray system utilizing 
2*theta/theta geometry and equipped with a copper target (λ = 1.54 Å) operated at 2.2 kW. 
The second method of characterization was transmission electron microscopy (TEM). 
Microtomed samples were embedded in an epoxy resin and then sliced to 80 nm thickness 
using a Leica Ultracut sliding ultramicrotome. Thin sections and particle samples were 
supported on copper grids with carbon film and examined in a Tecnai G2 F20 microscope 
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operated at 200 kV. Scanning electron micrographs were obtained using a FEI Quanta 250 
FEG scanning electron microscope     
 
Results and Discussion 
In order to establish the phase behavior of the silicate particle product, several 
experiments were designed and carried out including variation in TEOS concentration, 
CTAB concentration, synthesis temperature, oil-to-water ratio and weight percentage of AP 
stabilizer. The initial evaluation of the materials in these experiments was performed by 
powder XRD. The first set of experiments was performed by varying the concentration of 
CTAB around the value for the second critical micelle concentration (transition from 
micelles to long rods in hexagonally packed arrays).[14] Surprisingly, a material with some of 
the desired characteristics including a pore size of 7 nm was obtained in this first attempt 
(Fig. 1). It was not immediately clear from the analysis of the XRD  pattern whether or not 
the pore system in the material was of a 2D cubic or hexagonal structure due to the fact that 
when the hkl-indices for the peaks were compared with 2*theta values derived from 
calculations did not result  
    
Figure 1. Powder X-ray diffraction pattern of materials synthesized using variations in CTAB concentrations. 
The ratio of CTAB to silica precursor can be seen in the figure legend. 
82 
 
 
Figure 2. SEM (A) and TEM (B) micrographs of material 78-1 detailing the random particle morphology and 
pore structure. 
 
in a positive match for either cubic or hexagonal pore arrangement. Further analysis of the 
morphology using SEM and TEM observations revealed that this initial set of particles also 
possessed a wide distribution of particle sizes (Fig. 2A) and the pore structure did not appear 
to be uniform across all particles (Fig. 2B). In addition, the particle morphology was not 
limited to spheres or sphere-like particles and instead included ovoid particles and monolithic 
particles possessing no mesostructure. The next step was to control the amount of TEOS 
added to the solution, the presence of monolithic particles indicated that the capacity of the 
water phase of the emulsion to contain the current amount of TEOS had reached the 
saturation point. The results of the experiment yielded a particle with the most ordered 
structure and uniform morphology of any of the following studies (Fig. 3). The peak position  
 
Figure 3. X-Ray diffraction patterns for 79 series of reactions (A) in which the concentration of TEOS is 
varied. The figure legend shows the mol ratio of silica precursor to CTAB structure directing agent. Panel B 
shows the SEM micrograph of the material 79-1.  
  
A B 
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data obtained from the XRD pattern of these materials resulted in a relatively good match for 
a hexagonally close packed array of pores (Tab. 1). The incomplete matching of peak 
positions to hkl- indices led to samples of 79-1 to be embedded in an epoxy resin and 
microtomed so that thin slices of the particle could be examined to test whether multiple 
phases were still observable (Fig. 4). A third set of samples was prepared in which the 
weight% of AP was varied to determine if particle morphology could be better controlled by 
altering the amount of emulsion stabilizer. The peaks recorded in the powder XRD patterns 
did not shift position indicating that AP does not play an active role in determining the pore 
structure of the mesoporous silicate material (Fig. 5).  
To determine what role AP is performing in these experiments; SEM and TEM micrographs 
of the materials were examined (Fig. 6). This set of micrographs confirms that AP concentration 
affects the morphology of the particle. In the sample where the smallest weight percentage of AP is 
used, a spherical morphology is achieved but the particle size is found to vary from 200 nm up to 2 
μm (Fig. 6A and 6C). In the samples where the largest weight percentage of AP is used, a uniform 
particle size is obtained however the morphology deviates from spherical (Fig. 6B and 6D). 
 
Table 1. Calculations of the expected peak positions of an array of pores matching either 2D hexagonal or cubic 
phases. Cubic arrangement appears to give the closest values for calculated peak positions.  
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Figure 4. TEM images of particles in experiment number 79-1 at increasing magnifications of 10 kX (A), 42 
kX, and 160 kX. The red box shows the area examined in the images of increased magnification. Images of 
samples embedded in epoxy and then microtomed, the particle in panel D shows a cubic pattern with a 
matching fourier transform of the diffracted electrons (inset) while panel E shows a particle with a visually 
hexagonal pattern though the fourier transform of diffracted electrons for this sample is inconclusive (inset). 
 
In addition the edges of the particle are also roughened and the micrographs show that many of the 
particles are not completely formed or broken.   
Despite the fact that uniform morphology and a regular pore structure had been discovered in 
earlier experiments, further tests of temperature were carried out to ensure that room temperature 
synthesis was providing the best overall structure (Fig. 7). The results of this experiment clearly show 
that any increase in synthesis temperature results in the degradation of long range pore ordering 
followed eventually by the total loss of pores in the material.  Finally a synthetic phase diagram was 
derived 
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Figure 5. Powder XRD pattern of mesoporous materials prepared with different concentrations of emulsion 
stabilizer AP. Samples 82-1, 82-2, 82-3, 82-4 correspond to 0.03 wt%, 0.06 wt%, 0.15 wt% and 0.30 wt% 
(decane) respectively. 
   
 
Figure 6. Micrgraphs of materials synthesized using 0.03% wt (A and C) and using 0.30% wt (B and D) of 
emulsion stabilizing molecule, AP. Particle diameter varies greatly in A and C, while the spherical morphology 
is degraded in B and D. 
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Figure 7. Powder XRD pattern showing the effect of increasing temperature on the pore structure of 
mesoporous silica particles. The sample 80-1, 80-2, 80-3 and 80-4 are synthesized at 30oC, 40oC, 50oC, and 
60oC respectively. Intensity values are offset for clarity. 
 
Figure 8. Phase diagram for the synthesis of ca. 7 nm pore diameter mesoporous silica spheres. The orange oval 
represents conditions which produce the desired product. 
 
using the observations from the various analytical techniques (Fig. 8). A spherical mesoporous silica 
particle was successfully synthesized and characterized. Additionally a phase diagram was developed 
for to describe the conditions at which this particle could be synthesized. The spherical nature of the 
particle should enable the material to interact with biological systems without causing undue toxicity. 
In addition the increased pore size above the normal diameter from the MCM-41 type mesoporous 
silica particles pores (approx. 3 nm) should enable future researchers to encapsulate larger molecules 
such as proteins or enzymes in the pores.  
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II. Synthesis and Morphology Control of a Periodic Mesoporous 
Organosilica Derived from Benzobisoxazole-Bridged 
Alkoxysilanes 
Introduction 
Periodic mesoporous organosilicas (PMOs) represent a large class of materials 
originating from a common molecular precursor with the basic structure (RO)3Si—R’—
Si(OR)3.  These precursors are capable of producing highly ordered structures on both the 
molecular and supra-molecular levels.    On the supramolecular level, a wide range of 
morphologies have been synthesized from films to spherical particles, each with a range of 
pore sizes and pore arrangements.[15-18]  PMOs have also been reported containing a variety 
of organic groups that impart the materials with distinctive characteristics.   Organic groups 
having been successfully incorporated into PMOs include simple alkanes, alkenes, alkynes, 
metal complexes and conjugated molecules including benzene, naphthalene and anthracene 
derivatives.[19-26] Furthermore, it has been proven that several PMOs are capable of 
performing or enhancing catalytic reactions, temperature responsive materials and light 
harvesting materials.[26-28] PMO materials with luminescent properties have been recently 
reviewed by Tani et al.  indicating that interest in luminescent PMOs and their usefulness in a 
variety of devices have been increasing.[29]  
This current work focuses on the synthesis and morphology control of a PMO 
material containing 2,6-bis(methyl(3-aminopropyltriethoxy-silane))benzo(1,2-d,4,5-
d’)bisoxazole (MASBB) as the organic bridging group (Scheme 1).    
Scheme 1.  Synthesis silsesquioxane precursor via SN
 
2 of MASBB and 3-aminopropyltriethoxysilane.   
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Benzobisoxazoles (BBOs) represent a class of materials already researched as robust 
materials for alternative energy and mechanical applications; however the ability to process 
these materials into functioning devices such as solar cells and ballistic materials is generally 
an expensive and laborious process involving specialized hardware and strong acids.[30-32] 
Despite these limitations poly-benzobisoxazole based diodes are receiving increased 
attention due to their excellent ability to transfer electrons.[33] Many of the important sensing 
and photoreactive attributes displayed by BBO based polymers are due to the π - π stacking 
effects of adjacent polymer chains.[34] By incorporating BBOs into the pores of our PMOs we 
hope to be able to generate materials with many of the same opto-electric properties as BBO 
based polymers.   
 
All PMO materials were synthesized under the same general procedures which are as 
follows: synthesis of precursor silsesquioxane by SN2 reaction with 3-aminopropyltriethoxy-
silane followed by purification of PMO precursor via vacuum distillation.  An aqueous 
solution of cetyltrimethylammonium bromide (CTAB) and NaOH is then added to the still 
hot PMO precursor, followed by addition of tetraethylorthosilicate (TEOS).  The molar ratio 
of Si : CTAB : NaOH : H2O, in solution are as follows: 1 : 0.748 : 6.795 : 1385.  The solution 
is then stirred at 105oC for 4 days followed by condensation of the solution via adjustments 
of the pH between 9 and 11 with concentrated HCl.  Hydrothermal aging at 120oC in sealed 
Teflon bottles was carried out on several samples in attempts to further control the final 
morphology of the PMO.  The CTAB template was removed via high vacuum at 200oC and 
template extracted materials were compared with as-synthesized materials via TGA analysis 
in order to confirm removal of the surfactant and retention of MASBB group.   X-Ray 
powder diffraction patterns, TEM micrographs and nitrogen sorption isotherm experiments 
were used to characterize the PMO materials.    MASBB-based PMOs can be synthesized in 
such a way as to yield a crystalline organic phase and regular mesopores as shown in the 
powder XRD patterns in Figure 1. 
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Figure 1.   XRD pattern for materials synthesized with pH adjustment at 100o
 
C and 24 hours of aging.  Scan 
from 1 – 10 degrees 2 theta indicating mesoporosity of the material.   The inset shows a scan from 10 – 90 
degrees 2 theta indicating crystalline BBO domains. 
 
Figure 2.  XRD patterns for template-extracted materials.  Scan from 1 – 10 degrees 2 theta indicating 
mesoporosity of the material after template extraction.   The inset shows a scan from 10 – 90 degrees 2 theta 
indicating retention of crystalline MASBB domains after template extraction. 
The results of X-ray diffraction experiments show that mesoporosity of the materials 
is obtained in all samples while extended hexagonal ordering is only accessible at hydrolysis 
conditions of pH 10 to 11.  Crystallinity of the benzobisoxazole moiety can be obtained from 
hydrolyzing the homogenized solutions at a pH range of 9 to 10 (Figure 1).  Calcination at 
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temperatures higher than 200 oC both with and without the presence of vacuum results in the 
collapse of both mesopores and the dissociation of the crystalline domains in all materials.  
TEM analysis of the synthesized materials yields the following trends; sphere shaped 
materials resulted from high temperature condensation while a rod morphology is obtained 
from samples which are condensed at room temperature (Figure 3).  Hollow silicate materials 
have been synthesized previously using very basic conditions or swelling agents.[35-37]
In this study we have also successfully synthesized hollow PMO materials by 
hydrothermally aging the PMO-h11 or PMO-r10 solutions for 8 or more hours (Figure 4).   
  
   
Figure 3.  TEM micrograph showing the effect of condensation temperature on PMO morphology, (a.) room 
temperature condensation at pH 10 and (b.) 100 o
 
C condensation at pH 10 
Figure 4.  TEM micrograph showing the effect of aging on PMO morphology, (a.) room temperature 
condensation at pH 10 followed by 24 hour hydrothermal treatment, (b.) 100 o
In order to demonstrate a potential application of MASBBO-PMOs as chemical 
sensors, an experiment was carried out to determine the amount of fluorescence quenching 
that could be achieved by exposes the materials to 100 uM solutions of the common 
C condensation at pH 11 followed 
by 24 hour hydrothermal treatment. 
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explosive taggants 3-nitrotoluene (3-NT) and nitromethane (NM) in acetonitrile.  Both of 
these molecules exert room temperature vapor pressures well above that of TNT or other 
plastic explosive and are thusly used in the detection of explosives.[38-40]
 
  The pi interactions 
of the benzobisoxazole moiety and nitro group of the selected molecules results in 
fluorescence quenching of the MASBBO-PMO.  The UV-vis spectrum of MASBBO-PMO 
was first obtained in aqueous solution and in THF, and an absorption edge at 295 nm was 
selected as the fluorescence excitation wavelength.  Excitation of MASBBO-PMO at 295 nm 
results in two excitation peaks, one centered at 335 nm and the other at 440 nm (Fig. 5).    
Figure 5.  Fluorescence measurements of MASBB-PMO (250 μg/mL) exposed to 100 μM taggant/acetonitrile 
solutions and in acetonitrile (control). 
The total amount of quenching observed for 3-NT treated PMO is 20% ± 3.5% at 335 nm and 
22% ± 5.6% at 440 nm.  The total amount of fluorescence quenching for the NM treated 
PMO is 20% ±  1.2% at 335 nm and 21% ±  1.4%.  MASBBO-based PMOs have been 
successfully synthesized and their morphology and crystallinity carefully controlled using a 
variety of synthesis conditions.  This research provides a framework under which other 
PMOs may be prepared in order to take advantage forced-ordering of small molecules due to 
confinement.  These future materials may be used on opto-electronic, sensing and other 
devices.   
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Conclusion 
Two new mesoporous silicates have been successfully synthesized and characterized 
by a variety of techniques. The first structure is an improvement over the current large pore 
mesoporous silica nanoparticles in that the total synthesis time has been cut by approximately 
two thirds, the morphology of the particle is truly spherical and the structure can be generated 
at room temperature using materials with less total cost (if the decane is recovered and 
reused). The second type of particle represents a new class of potential electronic materials. 
Further experiments are required to determine whether or not it is possible to synthesize such 
a particle with a larger array of photo-active functional groups. Future research would 
develop a particle which may find applications in both solar cell development and light-
emitting diodes.   
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Chapter 4: Synthesis of a New Imidazole-Derived 
Copper Ligand for Copper Assisted Azide/Alkyne 
Cycloaddition  
Introduction 
N-heterocyclic carbenes (NHCs) represent a specific type of Fischer carbenes and 
have shown a diverse and expanding chemistry, specifically as ancillary ligands.  
Coordination of NHC ligands to a variety of metal centers has led to the generation of 
efficient and selective catalysts (reference, cite Grubbs obviously). Moreover, numerous 
methods for the synthesis of NHCs have been reported (reference), which has allowed for, 
among other things, the development of solid-supported NHC complexes.   It is this diversity 
of catalytic reactions that makes NHC chemistry so attractive for heterogeneous catalysis 
(HC). Utilizing a single carbine ligand numerous groups have shown it possible to catalyze 
over a dozen different reactions including Suzuki coupling (Pd),[1] amide bonds from 
alcohols (Ru),[2] hydroalkoxylation (Au),[3] transfer hydrogenation (Ir),[4] and O-arylation of 
aryl bromides (Rh).[5, 6]  The same NHC ligand can also be used to create pharmaceutically 
active compounds.[7]  One of the main goals of HC is to develop new “green” catalysts, 
which can be used in benign/aqueous solvents and are easily recoverable and recycled; to this 
effect we are attempting to develop a novel solid-supported Cu (I) NHC catalyst for the 1,4-
dipolar azide/alkyne cycloaddition (CuAAC).  
The Imidazole Derived NHC Ligand 
 The existence of stable NHC compounds was theorized in the 1960’s by Wanzlick et 
al. followed shortly thereafter by the first isolation of stable NHC-transition metal complex in 
the 1970’s by the groups of Wanzlick and Öfele.[8-10]  However, it was not until 1991 that the 
first stable diaminocarbene was synthesized by Arduengo et al.[11, 12]  The difficulty in 
preparation was owed to the propensity of diaminocarbenes to dimerize unless bulky R2 
groups were used to prevent dimer formation.  Later it was discovered that adequate 
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electronic stabilization of the carbene through σ-withdrawing atoms at the 4 and 5 positions 
yields stable, free NHCs by reducing the basicity of the carbene lone-pair.[13]  NHCs first 
gained notoriety as replacements for phosphine ligands and other strongly σ-donating ligands 
such as cyclopentadienyl.  A review by Crabtree highlights some differences between 
phosphine ligands and NHC ligands.[14]  One difference lies in the shape of the ligands. 
Phosphines are cone-shaped whereas NHCs are fan shaped resulting in much more steric 
interaction in the case of bis-chelating NHC ligands.  
NHCs are regarded as Fisher-type carbene complexes.  Fisher carbenes exist in the 
singlet ground state with a filled sp2-orbital a vacant p orbital on the carbene carbon.  In 
contrast, Schrock carbenes are found in a triplet ground-state and contain one electron in both 
the sp2 and p carbene orbitals (Figure 1A). A Fisher carbene is usually seen when there is a 
difference of greater than 40 kJ/mol between the  
 
Figure 1. A. Illustration of the differences in bonding between Fischer and Schrock carbenes. Fischer carbenes 
reside in a singlet ground state while Schrock carbenes have a triplet ground state. B. Representation of 
imidazole outlining important areas of substitution in the molecule. 
singlet and the triplet state. Owing to their different electronic structures, Fisher and Schrock 
carbenes interact differently with metal centers and the resulting carbene complexes display 
different reactivities.  Fisher carbenes are L-type ligands, which do not formally oxidize the 
metal center.  Moreover, the vacant p orbital on Fisher carbenes render them capable of π-
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back bonding to the metal center and susceptible to attack from nucleophilies.  Schrock 
carbenes are  X2 type ligands that formally oxidize the metal center by two, similar to O2-.[15] 
Unlike Fisher carbenes, Schrock carbenes tend to behave an nucleophilies.  Although NHCs 
derived from 1,3-imidazoles are usually classified as Fisher carbenes, there are two scenarios 
where they more closely resemble  Schrock-type carbenes. The two scenarios arise when 
switching from π-donating groups at R1 to π-accepting groups and by decreasing the 
oxidation state of the metal complex, thereby increasing the energy of the metal dπ-orbitals 
and reducing overlap with the empty π-accepting orbitals of the carbene (Fig. 1B).[15] 
Traditionally, the electron donating ability of a ligand has been quantified using the 
Tolman electronic parameter (TEP).[16]  In these experiments the carbonyl stretch of a 
M(CO)xL (where L is the ligand of interest) compound is measured. The TEP measures the 
amount of π-backbonding from the metal into the carbonyl. By increasing the amount of σ-
donating character from ligand L to the metal increases the amount of π-backbonding 
between the metal and the CO ligand.  Metal to carbon π-backbonding causes the strength of 
the carbon-oxygen bond to decrease, resulting in lower frequencies of the carbonyl main 
stretching mode. The bond dissociation energies or TEP values for M(CO)xNHC systems are 
usually compared with %V (percent metal volume buried) with a rough degree of correlation.  
In the case where significant discrepancies were found between TEP and %V, attempts to 
refine the correlation by measuring ΔH of CO dissociation often show greatly different 
energies for ligands having nearly identical TEP values.  One study by Gusev shows the 
theoretical TEPs for 76 different NHC ligands bonded to a Ni(CO)3 complex and adds a 
steric factor that more thoroughly explains aberrations in the data such as the propensity for 
1,3-di-t-butyl substituted NHC complexes to eliminate CO while imidazoles with 1,3-
diisopropyl substituents do not, despite having nearly identical TEP values.[17] In addition to 
steric contributions, Gusev’s study finds that electron donating and withdrawing substituents 
in the 4,5 positions also have significant contributions to the carbonyl stretching frequency.   
Further electronic-structure/function relationships are provided by Khamrov, whose 
works seeks to outline how both σ and π contributions at the 4 and 5 positions of imidazole 
effect the catalytic effeciences of rhodium and palladium NHC complexes.[18] The Rh-
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catalyzed hydroboration of substituted acetylenes with pinacolborane yielded clear trends for 
the phenylacetylene substrate. When σ –withdrawing groups were substituted at positions 4 
and 5, reaction yields increased compared to those with analagous π-withdrawing 
substituents.  However, no trend was detected for the reaction with the 1-hexyne substrate. 
While overall Heck-coupling efficiencies were low, an important distinction was observed 
during kinetic studies.  Unsubstituted NHCs were expected to be better than 4,5-
functionalized catalysts owing to their electron rich structure which increases the rate of the 
oxidative of addition of an aryl halide to Pd.[19] Indeed, fast saturation kinetics were observed 
for the unsubstituted NHC, but with strongly withdrawing CN substituents at the 4 and 5 
positions,    the life of the catalyst increased by almost 5-fold resulting in nearly 20% greater 
conversion. The cyano groups were theorized to stabilize the electron rich Pd0 resting state of 
the catalyst from unwanted oxidation.[18] These reactions demonstrated the extraordinary 
tunability of NHC ligand. 
While catalytic reactions with NHC coordination compounds were shown to undergo 
many of the same types of reactions traditionally accomplished with phosphine ligands, 
additional chelating groups bound to the NHC backbone can help to improve yields and 
make catalytic molecules more specific for different types of reactions.[20]  Additionally, 
NHC ligands with chiral or bulky substituents were shown to be effective for enantio- and 
stereoselective catalysis.  NHC pincer ligands have been synthesized with pyridyl, amine, 
thiol and phosphine chelating groups.  Most of these studies use nickel, palladium or 
ruthenium as the coordinated metal, and relatively little information exists on copper-based 
pincer chemistry.[21-24]  Results for some of these studies are summarized in Table 1.  
Palladium and nickel based catalysts have proven themselves effective for several types of 
reactions.  Several reviews of existing imidazole-derived NHC catalysts are available. 
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Entry Metal Ligand Reaction Yield EE E/Z reference 
1 Pd Am-C-Am Suzuki 17-38% a b Liao[25] 
2 Pd S-C-S Suzuki/Miyaura 64-88% a b Fliedel[26] 
3 Pd P-C-P hydroamination 67-99% 22-75% b Gischig[22] 
4 Pd Py-C-Py polymerization n ≈ 37 c a b Chen[27] 
5 Pd Py-C-Py Suzuki/Miyaura 99% a b Chen[28] 
6 Ni Py-C-Py Kumada-Corriu 60-99% a b Chen[28] 
7 Cu O-C-O conj. addition 99% 46-72% 1 : 9 - 20 : 1d Kehrli[29] 
8 Rh Py-C-Py t-hydrogenation 40-100% 0-83% b Newman[30] 
9 Rh Py-C-Py hydrogenation 0-99% 0-83% b Newman[30] 
Table 1. Various reactions catalyzed by NHC-pincer complexes. Abbreviations for NHC ligands are as follows;  
Am – amido, S – sulfur, P – phosphine, Py – pyridyl, O – ether. a  EE not reported, b E/Z not reported,  c average 
molecular repeat of polymer , d ratio of 1,2 : 1,4 substituted products.  
Heterogeneous NHC Catalysis 
The success of NHC molecules as catalysts has led to the development of several 
heterogeneous systems including polymer, organometallic structures and silica-supported 
catalysts.[31, 32]  Significant contributions to the field of solid supported NHC catalysts are 
summarized in Table 2.  Application of silica supported ruthenium-NHC complexes to 
hydrogen transfer reactions resulted in product yields and selectivities that were comparable 
to the analogous homogeneous system.[33] For the cyclopropanation of (blank with blank), a 
heterogenous asymmetric Ru-NHC system was more enantioselective than the corresponding 
homogeneous catalyst, albeit with decreased reactivity and longer times.[34]  Promising 
catalytic results were also reported for silica supported palladium NHC complexes.  Reports 
in heterogeneous Pd-NHCs for Suzuki couplings of phenyl iodides have shown excellent 
conversions in short times (20-50 minutes) and mild temperatures.[35]  The catalyst was 
shown to be able to be recycled up to 6 times with only a 10% loss in overall conversion 
efficiency.  Suzuki couplings of phenyl bromides also showed excellent conversion 
efficiencies although required longer times for more electron donating phenyl bromides. The 
same system was used for Heck couplings with high coupling efficiencies in short times but 
temperatures of 130oC were required for completion. Additionally, the solid support greatly 
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allowed for facile recycling of  the catalyst. Complexes grafted to SBA-15 (2D-hexagonal 
pores, ≈ 8  nm) showed only modest recyclability (4 trials) before significant loss of activity 
in Suzuki coupling, while complexes grafted to SBA-16 (3D-cubic pores,  ≈ 8  nm) showed 
high activity in up to 10 trials for Suzuki couplings and up to 8 trials in Heck couplings.  
Entry Support Metal Ligand Reaction 
mol % 
cat. 
Yield Trialsb EE E/Z reference 
1 
MCM-
41a 
Ru C-Py-Am hydrogenation   
70 - 
100% 
- 5-98% d 
del 
Pozo[34] 
2 
MCM-
41a 
Ru C-Py-Am cyclopropanation   
10 - 
100% 
- 5-77% 
1:1 - 
100:1 
del 
Pozo[33] 
3 
MCM-
41a 
Ru C-Py-N Dehydrogenation   0 - 100% - c d 
del 
Pozo[33] 
4 silica Pd R-C-R Suzuki 0.2 79 - 84% 2 c d Tyrrell[36] 
5 SBA-16a Pd R-C-R Suzuki 0.01 87 - 99% 10 c d Yang[37] 
6 SBA-15a Pd R-C-R Suzuki 0.01 98% 3 c d Yang[37] 
7 silica Pd R-C-R Suzuki 0.01 95% 2 c d Yang[37] 
8 SBA-16a Pd R-C-R Heck 0.01 76 - 97% 8 c d Yang[37] 
9 
MCM-
41a 
Pd R-C-R Suzuki 
0.05 - 
1.0 
93 - 
100% 
6 c d Alam[35] 
10 
MCM-
41a 
Pd R-C-R Hydrogenation 0.0001 100% 3 c > 80%e Liu[38] 
11 silica Pd R-C-C-R Heck 0.0001 78 - 96% 4 c d Karimi[39] 
12 MOF Pd R-C-R conj. Umpolung - 46 - 84% 5 c 01:01.5 Rose[32] 
13 MOF Pd C-C Strecker 4 51 - 99% 3 c c Choi[40] 
Table 2. Various reactions catalyzed by metal-NHC complexes immobilized on solid substrates. MOF = Metal 
Organic Framework. a designates a specific mesoporous silicate. b Trials in which catalyst activity dropped 
below 50% of the starting activity are dropped from the total count. c EE data unavailable. d E/Z data 
unavailable. e represents selectivity of propanol over propanal products 
Han et al. recently prepared a collection of imidazolium-ionic liquid based NHCs linked to 
an amorphous silica particle with 2D-hexagonal pore framework. Their work showed that the 
ionic liquid Pd-NHCs had a equal efficiencies to Pd/C for hydrogenating 1-hexene and 
cyclohexene but showed approximately 20% more conversion with allyl alcohol as the 
substrate with 1-propanol/propanal selectivities  more than 5% greater than Pd/C.[38]  With 
increases in the types and synthetic pathways to NHC molecules and the advantages of 
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heterogeneous and “green” catalysis, this area is expected to greatly increase in scope over 
the next decade.       
 
Copper Catalyzed Azide/Alkyne Coupling (CuAAC) Reactions 
For over a decade the CuAAC reaction has been one of the best studied of the “click” 
reactions. The reaction has proven to be useful in a wide variety of conditions with a wide 
variety of substrates.  The azide/alkyne coupling reaction has been employed to attach 
molecules to surfaces and to synthesize new materials; the catalysts have also been shown to 
be effective when immobilized onto solid supports.  Azide/alkyne coupling reactions have 
been successfully performed using a variety of simple copper salts alone. The addition of 
ancillary ligands also allow the synthesis of molecules impossible when using only simple 
copper salts.[41]  Amine, phosphine and NHC ligands have been utilized to affect the rates 
and selectivities of some CuAAC reactions.  
 
CuAAC reactions have been proposed to proceed via a variety of different reactions 
pathways depending on copper precursor, ligand, base and solvent used.[42-46]  In all cases, it 
is widely regarded that ligands generally help to protect Cu (I) species from oxidation and 
basic amine ligands add electron density to the metal center (Figure 2).[47]  Additional 
electron density was hypothesized to accelerate the rate of the triazole forming step. [50] 
In general, multi-dentate ligands provide the best acceleration due to their ability to 
stabilize the resting form of the catalyst.  The best examples of accelerating ligands to date 
are those molecules with structures (Hy)3N.  Early results by Fokin indicate that tris-
(benzyltriazolylmethyl)amine (TBTA) provides the most protection from aerobic conditions 
coupled with a strong rate-enhancement effect.[51] Although strongly donating ligands were 
proposed to increase reaction rate, the use of strongly-coordinating multi-dentate ligands 
such as tris-pyridylamine and tris-methylcarboxylamine resulted in slower CuAAC 
reactions.[52] It is thusly theorized that weak-binding ligands are necessary to permit binding 
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Figure 2. A. Original CuAAC reaction mechanism proposed by Sharpless and Fokin in 2002.[47] B. One of 
several recently proposed reaction mechanisms with a dinuclear copper complex. The dinuclear complex is in 
response to observed second order rate constants with respect to copper and the difference in reactivities of 
mono and bis-alkyne substrates. The copper molecules may be directly bonded or bridged by ligands, 
depending on the reaction conditions.[48, 49]  
of the substrate to the catalyst.  Multi-denticity is required to keep the metal atom in the 
coordination environment of the ligand.  Furthermore, in this study, it was found that 
tridentate ligands with a bulky side group (table 3. Ent #) and ligands bearing pendant 
carboxylic acid groups increased reaction rates relative to those using the TBTA ligand. The 
rate enhancement was explained using the preferred coordination geometry of Cu (I) 
complexes; the strongly chelating carboxylic acid displaces an imidazole ligand providing 
better overall geometry for substrate binding.  Carboxylic acids have also been shown to 
increase the rate of imidazole protonation in CuAAC reactions leading to an overall increase 
in reaction rate.[53]  In the case of a non-bonding R-group, the ligand is more able to maintain 
the tetrahedral geometry of Cu (I) while protecting the Cu center from oxidation and 
allowing the substrate to bind without the displacement of ligand.   
While rare in the literature, Cu complexes bearing NHC ligands have been found to 
catalyze CuAAC reactions.  The most effective catalyst was (SIMes)CuBr, which afforded 
products in yields up to 98% in approximately 20 minutes reaction times under optimized 
conditions.[54] This ligand has also been shown to be effective at catalyzing the reactions 
between azides and internal alkynes, presumably through strong σ-donating character of the 
NHC helping to stabilize the Cu-alkyne π-complex.[55]   
103 
 
Heterogeneous CuAAC Catalysts 
One of the main driving forces behind the development of a heterogeneous CuAAC 
system is the reactions wide use in biochemical applications where copper concentrations 
must be tightly controlled and can quickly reach toxic levels.[56, 57]  The overall versatility 
and reliability of the CuAAC reaction naturally lends itself to studies in heterogeneous 
systems. Active catalysts have been prepared on a number of substrates including polymer, 
charcoal, silica and MOFs.[58-61]  Important studies on heterogeneous CuAAC are 
summarized in Table 4.  Although reports of silica supported CuAAC catalysts are quite rare, 
the systems that have been developed gave promising results.    
Entry Support Ligand mol % cat. Yield Trialsb reference 
1 polymer TBTA 0.001 a 7 Lammens [58] 
2 polymer - - 66 - 98% - Buckley [49] 
3 charcoal - 10 92 - 99% 3 Lipshutz [59] 
4 zeolite - 10 52 - 94% - Chassaing[62] 
5 zeolite - - 57 - 98% 4 Beneteau [63] 
6 MOF - 0.1 37 - 99% 2 Luz [64] 
7 SiO2 BPA 0.05 - 1.5 86 - 99% 5 Megia-Fernandez[65] 
8 SiO2 DEA 1 29 - 70% 3 Cabrero-Antonino[66] 
9 SiO2 Cu3N - 60 - 91% 5 Lee [67] 
10 SiO2 PEI(Cu) -  60-98% 3 Veerakumar[60] 
Table 4. Various CuAAC reactions using heterogeneous copper catalysts. bThe number of trials reported are the 
number of subsequent reactions that can be run before the product synthesized drops below 50% of the original 
value. 
Two recent reports use copper nanoparticles immobilized on silica.  The first example 
uses simple copper nanoparticles stabilized with polyethylenimine on simple silica 
spheres.[60]  Results of cycloaddition reactions show greater than 90% yields for a variety of 
substituted azides.  Additionally, this catalyst was evaluated for C-S cross coupling with high 
yields (>80%) for all substrates. The second example utilizes copper nitride particles 
immobilized on mesoporous silica.[67] This system also incorporates a superparamagnetic 
Fe3N for the magnet-assisted removal of the catalyst.  Moderate yields of cycloaddition 
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products (72 – 91%) were obtained for sets of highly substituted azides and alkynes.  
Reaction times for this catalyst were excessive with some systems  requiring 14 days for 82% 
yields.  The shortest reaction time in the study was 12 hours for the triazole product 
containing 1,4-bisphenyl substitution.  The only example ligand accelerated CuAAC on 
mesoporous silica comes from the work of Cabrero-Antonino et al.[66] This group synthesized 
a hybrid silica/organic structure using either a diethylamine (DEA)(sodium ascorbate added 
to reduce Cu (II)) or a Tröger base silsequioxane molecule as the copper chelating moiety.  
Product yields were low for the two systems with DEA producing a 70% yield and the 
Tröger base resulting in a 53% yield in 24 hour reactions.  
It is noteworthy that the three studies of CuAAC catalysts on silica were all reported 
within the last year, indicating a new interest in this area of research.  Additionally, the 
reported yields for all silica systems were lower than those for homogeneous systems, which 
allows for much additional room to synthesize and optimize new silica supported CuAAC 
catalysts. Considering the promise shown for NHC accelerated CuAAC and the preliminary 
reports of silica supported “click” catalysts, we endeavored to synthesize several unique 1,3-
bispyridyl substituted imidazolium molecules for their eventual application as catalysts 
(Figure 4). In addition, we hypothesize that due to the fact that the CuAAC ligand in this  
 
Figure 4: The structure of the final products in this study. The 4,5-substitution ‘R’ can be any organic molecule 
allowing for the tethering of the ligand to the mesoporous silica support. In the case of CuAAC reactions M = 
Cu. 
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study will be immobilized on the solid support, mechanistic work in determining whether a 
bi-nuclear or mono-nuclear copper transition species will also be possible. The structure 
pictured in Fig. 4 is unreported except when positions 4 and 5 are hydrogen. Currently, 
several linking moieties have been hypothesized which will allow for relationships between 
4,5 substitution and catalytic efficiency and/or product distribution to be drawn.  
 The ability for NHC ligands to catalyze such a wide variety of reactions and the 
general utility and dependability of CuAAC reactions has led to the proposal of a 
heterogeneous system comprising a copper coordinated NHC ligand linked to the surface of a 
mesoporous silica nanoparticle (MSN). In addition, MSN supported catalysts have been 
shown to be able to catalyze tandem reactions that are normally in which the catalysts are 
incompatible, such as subsequent acid-base reactions.[68] Furthermore MSN supported 
catalysts have also been shown to be effective at providing enatioselectivity as well as being 
able to increase product yield through secondary functionalization of the silica surface.[69, 70] 
These attributes, in addition to the arguments of catalyst recovery and recyclability have led 
us to propose this new NHC-MSN system. The project is in currently in its rudimentary 
stages and no supported catalyst has been synthesized however, important precursors have 
been synthesized and a test of the ability for the 1,3-methylpyridine-(4,5-H,H)-imidazole 
copper ligand to catalyze the CuAAC reaction have been performed. 
 
Experimental 
Silver oxide, potassium iodide, potassium periodate, potassium chloride, sodium 
carbonate and 12 M HCl were purchased from Sigma Aldrich and used without further 
purification. 1H-imidazole-4,5-dicarboxylic acid and 1H-imidazole-4,5-dimethanol were 
purchased from TCI America and used without purification. Ammonium hexafluorphosphine 
and 2-bromomethylpyridine were purchased from Acros Organics and used without further 
purification. Finely powdered copper metal was received in an unmarked vial as a donation 
from the Larock group. Water used is purified with a Millipore® system until 18 Mohm 
resistance is reached.  
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Potassium iododichloride (KICl2) solution: Synthesis of this solution was 
accomplished using the published procedure by Larsen et al.[71]  In a 2-neck one liter flask, 
71 g (0.33 mol.) of potassium iodate, 40 g of potassium chloride and 5 mL of concentrated 
hydrochloric acid is added to 80 mL of water and allowed to dissolve. To an Erlenmeyer 
flask, 111 g (0.66 mol.) of potassium iodide is dissolved in 90 mL of water and then placed 
in an addition funnel; the flask is washed once with 10 mL of water. To a second addition 
funnel, 170 mL of conc. hydrochloric acid is added. The two addition funnels are fixed to the 
2-neck one liter flask equipped with a stir bar and then reagents are added dropwise 
simultaneously. It was found to be vitally important to control the rate of addition so that it 
takes 3-4 hour to complete each addition in order to avoid excess generation of heat and the 
subsequent release of chlorine gas, attempting to cool the reaction in an ice bath results in the 
precipitation of solid I2. Water is then added to the solution to make 500 mL, resulting in a 2 
M solution of KICl2.   
    1H-4,5-diiodoimidazole (1): Synthesis of this precursor was carried out according 
to the procedure published by Garden et al.[72] An aqueous solution of imidazole (30 mmol, 
0.3 M) is added dropwise to 37 mL of the 2 M KICl2 solution via addition funnel. After 
addition the reaction is stirred an additional 6 hours and 2 M NaOH is added to the flask until 
the solids are completely dissolved. The solution is then adjusted to pH 10 by dropwise 
addition of concentrated HCl. This results in the precipitation of the desired product which is 
then recrystallized from methanol to afford the purified 4,5-diiodoimidazole in 90% yield.   
1,3-methylpyridineimidazole bromide (2): Synthesis of this ligand was 
accomplished by first placing 500 mg (7.34 mmol) of imidazole and 3.46 g (32.6 mmol) 
sodium carbonate (dibasic) in 160 mL of anhydrous acetonitrile and stirring for 30 minutes. 
To the suspension, 4.12 g (16.3 mmol) of 2-bromomethylpyridine is added and the mixture 
heated to reflux and allowed to react for 48 hours under argon atmosphere. Acetonitrile is 
then removed via rotovap and the sticky solid is dissolved in a minimum of CH2Cl2. This 
solution is then placed in a one liter beaker and the CH2Cl2 is allowed to evaporate leaving a 
purple/red film. This film is then triturated in approx. 500 mL of THF to afford the final 
product in approximately 75% yield.  
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1,3-methylpyridineimidazole silver bromide (2a): This compound is synthesized by 
dissolving 1,3-methylpyridineimidazole bromide in methanol and adding 1.5 equivalents of 
Ag2O. This solution is stirred for four hours and then filtered to remove excess Ag2O to give 
the product. 
1,3-methylpyridineimidazole silver hexafluorophospine (2b): 1,3-
methylpyridineimidazole silver bromide is dissolved in water and 2 equivalents of 
ammonium hexafluorophospine are added to the flask and allowed to stir for 2 hours. The 
product appears as an oil in the bottom of the flask and is extracted into CH2Cl2. The organic 
layer is dried over MgSO4, filtered and rotovapped to yield the desired product. 
1,3-methylpyridineimidazole copper hexafluorophospine (2c): 1,3-
methylpyridineimidazole silver hexafluorophospine is added t a flask containing acetonitrile 
and excess powdered copper. This reaction is allowed to stir overnight and is then filtered to 
remove excess copper and precipitated AgBr salts. The filtrate is then rotovapped to dryness 
to yield the desired product. 
1,3-methylpyridine-4,5-diiodoimidazolium bromide (3): Synthesis of this ligand 
was accomplished by first placing 500 mg (1.56 mmol) and 735 mg (6.94 mmol) of 
disodiumcarbonate in 80 mL of anhydrous acetonitrile and stirring for 30 minutes. To the 
suspension is added 877 mg (3.47 mmol) 2-bromomethylpyridine and the mixture is heated 
to reflux and allowed to react for 48 hours under argon atmosphere. Acetonitrile is then 
removed via rotovap and the sticky solid is dissolved in a minimum of CH2Cl2. This solution 
is then added dropwise to ice cold diethyl ether and filtered. The product is unstable to light 
and atmosphere and is decanted under an argon atmosphere and redissolved in 
methypyrrolidone to be used immediately in the next reaction step.  
1,3-methylpyridine-4,5-di(acetyltrimethylsilyl)imidazolium bromide 
CuAAC catalysis: In a 20 mL scintillation vial containing 10 mL of water, 50 mg 
(0.159 mmol) of catalyst is added followed by 1.0 mmol of phenylacetylene, 1.0 mmol of 
benzylchloride, and 1.0 mmol of sodium azide. This mixture is allowed to stir for 24 hours 
and is then extracted with ether to remove the catalyst. The aqueous layer is then extracted 3 
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times with ethylacetate and the organic layer is dried over MgSO4 and filtered. The filtered 
solution is rotovapped to dryness and the crude is collected and analyzed via proton NMR to 
determine whether or not product is present in the mixture. 
Results and Discussion 
Of the compounds synthesized in this project, only compound 2c was tested for to 
determine whether catalysis of the CuAAC reaction could be achieved. To this effect, it was 
observed that the catalytic reaction did proceed, albeit not to completion (figure 5). It is 
hypothesized that the main reasons behind the incomplete reaction were two-fold; the first 
reason being the lack of solubility of the catalytic ligand itself. While an excess (10 mol%) of 
the catalyst is added to the aqueous solution, a ksp value of 10-3 mol L-1 could easily reduce 
the amount of catalyst to less than 0. 1 mol%. The second reason is the mass transfer and 
eventual precipitation of the triazole products. During the course of the catalytic reaction it 
was observed that the triazole product began to precipitate quickly from the aqueous solution. 
The precipitate quickly coated visible particles of catalyst resulting in a yellow waxy 
substance at the bottom of the reaction vessel. This precipitate could easily prevent substrates 
from reaching the catalyst and preventing further reaction.  
  
Figure 5. Proton NMR of the crude mixture resulting from the CuAAC catalytic testing using compound 2c as 
the catalyst. 
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Initially, the goal was to synthesize the ligand from 4,5-dicarboxyimidazole, this 
would have provided the shortest and one of the cheapest routes to a ligand capable of being 
incorporated into an MSN (scheme 1). Unfortunately it was discovered that reaction with 2-
bromomethylpyridine resulted in  
 
Scheme 1. Initial proposed scheme for preparation of the tridentate NHC ligand. The abbreviation 3-APTES 
stands for 3-aminopropyltriethoxysilane 
only the monosubstituted 4,5-dicarboxyimidazole due to the deactivation of the nucleophilic 
nitrogens via electron withdrawing effects of the conjugated carboxyl groups. This led to the 
proposition of several other precursors including the following molecules seen in figure 6. It 
is hypothesized that molecule 3 could be reacted under Sonogashira conditions to afford 
   
Figure 6. Molecules proposed after the initial failure to synthesize the product in step 2 of scheme 1.  
the amine terminated product (scheme 2), followed by reaction with 3-
isocyanatopropyltriethoxy silane to yield a product capable of being linked to an MSN. It is 
known that palladium will coordinate with NHC ligands over phosphine ligands which 
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makes the first reaction in scheme 2 particularly interesting as the metallated product may be 
self-catalyzing as seen in the introduction where NHC-Pd complexes have been shown to be  
 
Scheme 2. Proposed reactions to alkoxysilane terminated NHC ligands for incorporation with MSNs. 
Abbreviations in the scheme are as follows: 3-ICPTES = 3-isocyanatopropyltriethoxysilane, 3IPTES = 3-
iodopropyltriethoxysilane 
active Sonogashira catalysts. The second reaction, lithium halogen exchange is much simpler 
though generating dianions on conjugated molecules is typically quite difficult (see chapter 
3, section 2).  Molecule 4 also presents several synthetic pathways to alkoxysilane terminated 
products although a simple one-step reaction is outlined in scheme 3. In this case, 4 would be 
added to 3-glycidoxypropyltriethoxysilane and the desired product should form  
  
Scheme 3. The reaction of 4 with 3-glycidoxypropyltriethoxysilane (3-GPTES) to yield the desired product. 
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spontaneously. The substrate 3-GPTES could also be reacted with the lithiated product in 
scheme 2 to provide the anti-Markovnikov substituted product.  
Conclusion 
The successful synthesis of multiple ligand precursors enables future researchers to 
use different synthetic strategies in linking the tridentate-NHC ligand to the surface of MSN. 
In addition, while only 4,5-disubstituted products have been shown here, monosubstitution at 
either the 4 or 5 position would also provide another variable for study. The ability to change 
the metal center in the NHC ligand should also enable this system to be active for many 
different catalytic reactions. Furthermore, modification of the surface of the MSN should 
enable us to fine tune the reaction parameters to make many of the catalytic reactions 
enatioselective or to force away products and side products allowing the equilibrium of the 
reaction to be shifted toward making more product. When all of the aspects of this system are 
taken as a whole, this project has the potential to be one of the most powerful catalytic 
devices that has yet been synthesized.     
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Chapter 5: General Conclusions 
 The field of research into the applications of mesoporous silicates has proven to be a 
popular avenue of study for the last two decades. The ability to functionalize these 
mesoporous silicates for specific applications continues to drive research, both in terms of 
fundamental materials research in generating new types of silicate materials for specific 
applications and research into probing and affecting the mechanisms of catalytic and 
biological systems. 
 The first chapter of this thesis outlines the current studies into the toxicity of 
mesoporous silica nanoparticles (MSNs) using in vitro and in vivo assays. Due to the variety 
of mesoporous silicate particles that are being evaluated, a general conclusion for the bio-
safety of these nanoparticles cannot be derived. What can be derived from these studies is 
that current toxicological research involving MSNs (and indeed other nanoparticles) needs to 
be evaluated on a uniform set of standards. Nanoparticles of all types are proliferating in 
research and driving new fields, if toxicity standards are not decided upon early in this 
research, promising areas of study will be delayed due to the lack of regulatory control. 
Many of these lines of research are reviewed at the end of the chapter and include devices 
capable of targeting specific cells, improving in vivo imaging, and releasing pharmaceuticals 
in response to a particular trigger. Advances in these areas of research coupled with good 
regulatory controls will enable MSNs to be used as reliable prototype systems for years to 
come.  
 A new MSN functionalization for interfacing with biological system has been 
successfully developed and this system applied to improve the biocompatibility of MSNs 
with red blood cells (RBCs). The first part of chapter 2 outlines the synthesis and preliminary 
data involved with toxicity of a lipid bilayer coated MSN (LB-MSN). These LB-MSNs were 
then demonstrated to be capable of controlled release of fluorescein on exposure of the 
particles to a disulfide reducing agent. Additionally, the endocytosis of LB-MSN particles 
was observed using flow cytometry and confocal microscopy. These observations all support 
the hypothesis that LB-MSNs may be used as a drug delivery device. The second part of 
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chapter 2 highlights the ability of tuning the lipid bilayer composition to increase the 
biocompatibility of a large pore (l-MSN) mesoporous silica particle. In this study, the l-MSN, 
which had proved to be toxic towards red blood cell in an early study, is functionalized with 
two different compositions of lipid bilayer; one consisting entirely of lipids with 
phosphatidylcholine headgroups (DPPC) and the other consisting of a mixture of 
phosphorylated lipids (mRBC) which more accurately approximates the composition of the 
outer leaflet of the RBC membrane. It was shown that simply coating the l-MSN with a lipid 
bilayer remediates the propensity of the particles to cause haemolysis although observations 
with SEM indicate that damage to the cells (spiculation) is still occurring. Particles coated 
with the mRBC bilayer also show no haemolysis and RBCs remain largely undamaged by 
SEM observation. In addition to the synthesis of a new generation of potential drug delivery 
vehicles, we have shown that careful observations of many parameters is necessary to 
conclude that a material is biocompatible and that the current standard of haemocompatibility 
(haemolysis) may not be enough to make this evaluation. 
 The third chapter of this thesis details the synthesis of new types of mesoporous 
silicates. The first section deals with the synthesis of unfunctionalized mesoporous silica 
particles using water-in-oil emulsion (W/O). These emulsion systems have proven useful for 
generating particles with well controlled spherical morphology and regular porosity with 
pore diameters approaching 8 nm. In addition these particles can be synthesized at room 
temperature and in is little as 6 hours. This is a significant advancement over the synthesis of 
similar particle types which often rely on high synthesis temperatures, even higher aging 
temperatures and extended synthesis times of 24 hours or greater. The second part of the 
chapter deals with the synthesis of a new type of periodic mesoporous organosilica (PMO). 
This new PMO material represents a model material for future silicates containing light 
harvesting or light emitting conjugated organic molecules. Indeed, since this study was 
completed, the synthesis of a solar cell using similar of chemistry has been reported, 
indicating that the materials may have promise in future devices.[1] 
 The final chapter of this thesis deals with the synthesis of a new N-heterocyclic 
carbene (NHC) derived from imidazole as a heterogeneous catalytic system. The MSN-
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catalysis is being designed to affect the copper-mediated acetylene-azide cross-coupling 
reaction (CuAAC). While only rudimentary progress has been made with the project to date, 
early reports are promising as the model catalyst is capable of catalyzing this reaction 
homogeneously. Further work on this project will involve mostly methods to reliably affect 
substitution of the 4 and 5 position of the 1,3-substituted imidazole, and then to link the 
product to the surface of MSNs. The imidazole framework provides an NHC platform 
capable of coordinating a wide variety of metals, thereby allowing one ligand access to many 
different types of catalytic reactions. This coupled with the ability of MSNs to serve as 
platforms for heterogeneous catalysis should result in one of the most powerful catalytic 
systems in the field.  
 For over 20 years, mesoporous silicates have proven their usefulness in catalysis, 
biology, and energy applications. The main reasons for their success are the relative ease of 
synthesis along with the ability to modify the surface of the particle with a wide array of 
functional ligands. As new catalysts, biological targets, and energy harvesting/light 
producing molecules are discovered, scientist will be working with mesoporous silicates to 
see if the high surface area, controllable pore size, pore structure and particle morphology 
can improve the performance and possibly discover new applications of the aforementioned 
molecules.        
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